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ABSTRACT
Recent advances in global gene expression measurement and the development of large-
scale public repositories for storage of such data have made a wealth of information
available to researchers. While one gene expression study may lack sufficient replicates
to make statistically significant pronouncements, the combination of studies through
meta-analysis can yield results with a much greater likelihood of accuracy. In order
to combine multiple sets of data, one must first address the issue of cross-comparison
between global gene expression platforms, as well as resolve the issue of repeated
measures (multiple probes representing the same gene) within each platform. In this
work, I present computational methods for probe reannotation and scoring and for
redundant probe consolidation that together allow for greatly improved access to data
for meta-analysis. I also present an example of the application of these methods, in
the analysis of the gene expression regulated by estrogen across multiple cell types.
Estrogen, a steroid hormone, interacts with its receptors to regulate gene tran-
vi
scription in both direct and indirect manners. Estrogen has the effect of increasing
proliferation in some tissues, while inhibiting proliferation or increasing apoptosis
in others. How estrogen achieves these highly divergent results remains unclear.
Through meta-analysis of gene expression experiments across multiple cell types, I
show that patterns of estrogen regulation in many tissues involve the same key genes
and pathways, including cell cycle, p53 signaling, and TGFβ signaling pathways.
However, regulation in different cell types can result from regulation of different
genes, or the same genes regulated in different directions. Many patterns of gene
regulation support known physiological consequences of estrogen on these tissues. In
particular, genes promoting proliferation are upregulated in uterus and certain breast
and ovarian cancer cell lines. One gene, thrombospondin-1, is up-regulated in eleven
out of nineteen cell types and may be a key player in regulating proliferation in re-
sponse to estrogen. Results in other cell types are unexpected. Most notably, neither
genes promoting nor inhibiting proliferation are differentially regulated upon estrogen
treatment in vascular smooth muscle cells, despite estrogen inhibiting proliferation of
these cells.
vii
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1Chapter 1
Introduction
1.1 Effects of Estrogen
Estrogen is a steroid hormone that is found in both males and females and has a
wide variety of effects on different organs and systems (Table 1.1). Estrogen is best
known for its role in the development and function of the female reproductive organs.
However, estrogen is also known to have effects on mammalian bone, brain, thymus,
lung, liver, prostate, and the cardiovascular system. With the cessation of estrogen
production in women at menopause, women experience increased risk of osteoporosis,
metabolic syndrome, and cardiovascular disease, leading to the hypothesis that estro-
gen plays some role in preventing these diseases in pre-menopausal women. Recent
research has shown that loss of estrogen with age occurs in men as well as women,
and may play a role in metabolic changes in both sexes (Finkelstein et al., 2013).
To understand the role of estrogen in health and disease, the cellular and molecular
effects of estrogen must be examined.
1.1.1 Cellular Effects of Estrogen
Estrogen can both activate and inhibit cell proliferation and drive apoptosis in differ-
ent cell types. Estrogen is known to have these opposite effects on different cell types
within the same tissue. For instance, in maintaining bone health, estrogen stimulates
osteoblasts, the cells that build bone, and inhibits osteoclasts, the cells that break
down bone. This maintains a healthy balance of bone remodeling, ensuring adequate
2bone strength.
Of particular interest is the effect of estrogen on the cardiovascular system. Most
(over 60%) of deaths from cardiac death are classified as “sudden cardiac death,”
occurring in an emergency room or before the victim reaches a hospital; clearly pre-
vention of cardiac disease is of paramount concern (Zheng et al., 2001) Cardiovascular
disease is the leading cause of death for both men and women in the United States,
however, the relative disease histories of men and women show that women have a re-
duced risk of cardiovascular disease compared to men in the years before menopause.
This observation has been further born out by animal model studies as well as observa-
tional clinical studies (Hodgin and Maeda, 2002). An understanding of the molecular
mechanisms of the atheroprotective effects of estrogen in premenopausal women, and
the changes in those mechanisms that occur after prolonged periods without estrogen,
would help elucidate potential targets for drug therapies to recapitulate the beneficial
effects of post-menopause estrogen administration.
1.1.2 Molecular Effects of Estrogen
Estrogens are members of the steroid class of hormones and as such can pass eas-
ily through the cell membrane into target cells. There are three known modes of
action by which estrogen can affect the cell: direct and indirect genomic actions,
and nongenomic actions. All three involve the binding of estrogen to estrogen recep-
tors (ERs), members of the nuclear hormone receptor family which (usually) act as
ligand-activated transcription factors. There are two known types of estrogen recep-
tors, ERα and ERβ. ERα and ERβ have different patterns of expression in different
tissues and so impact gene expression in these tissues in different ways. The actions
of ERα and β are also influenced by the presence of coactivators and corepressors,
further complicating the tissue-specific estrogen regulatory patterns.
3Genomic effects
The main mode of action is direct genomic transcription activation, in which estrogen
(mainly 17β-estradiol) binds to “free” (i.e., not bound to DNA) ER in the nucleus.
Like most steroid hormone receptors, ER localizes mainly to the nucleus, where it
is bound to a complex of heat shock and other proteins (HSP complex). Upon lig-
and binding, the HSP complex is released and the ER dimerizes, at which point it
becomes “activated” and can bind to promoter elements called estrogen responsive
elements (EREs) (Mendelsohn, 2002). ERα, but not β, is also capable of binding an-
other response element, the SF-1 response element (Bjornstrom and Sjoberg, 2005).
Putative EREs have also been identified in the mitchondrial genome. That fact, to-
gether with the detection of ER localized to the mitochondria and observed increases
in mitochondrial-DNA-encoded transcripts in response to estrogen, provides evidence
for the direct involvement of ER in gene expression of mitochodrial genes (Chen and
Yager, 2004).
A second mode of action is indirect genomic transcription activation, in which
ligand-bound ERs regulate transcription through protein-protein interaction (PPI)
with other transcription factors. Activation of transcription via this type of PPI has
been observed with Fos and Jun at AP-1 sites of several genes; repression of transcrip-
tion via AP-1 sites has also been observed. Similar ERE-independent transcription
regulation by estrogen has been show with Sp-2, NF-κB, C/EBPβ, and GATA-1
(Bjornstrom and Sjoberg, 2005).
Non-genomic effects
It has been demonstrated that estrogen and ER can also exhibit non-genomic effects
in the cell as well as the classical nuclear ones. In this mode, estrogen binds to ER
localized at/near the cell membrane and activates a signaling cascade pathway (for
4example, the MAPK pathway) via interaction with an alternate estrogen receptor,
GPER, formerly known as GPR30 (Prossnitz and Maggiolini, 2009).
A total understanding of estrogen regulation of cellular activity is in unraveling the
interactions of the above modes of action. For instance, the activation of various signal
cascade pathways may in fact have an indirect genomic effect in addition to the acute
effects. Activation of the MAPK pathway by estrogen can lead to the activation via
phosphorylation of the transcription factors Elk-1, C/EBPβ, and CREB, as well as the
AP-1 complex. Additionally, nuclear ERα and β can themselves be phosphorylated
by the kinases in the MAPK pathway (e.g., ERK), resulting in crosstalk between
extranuclear and nuclear ER. Activation of nuclear ER by ERK can also happen in
the absence of estrogen, leading to ligand-independent ER activity (Levin, 2005).
One key example of the extranuclear action of estrogen is the ability of ligand-
activated ERα to cause a rapid activation of the signal transduction pathway leading
to endothelial nitric oxide synthase (eNOS) activation in the vascular endothelium
(Chen et al., 1999). The activation of eNOS causes the endothelial cells to release
nitric oxide (NO), which causes relaxation of the adjoining vascular smooth muscle
cells and thus vasodilation. NO also prevents platelet activation, which, together
with its vasodilatory effects, provides a powerful protective system for the vasculature
(Mendelsohn, 2000).
In order to elucidate the mechanisms by which estrogen controls cell fate in various
tissues, including the vasculature, gene expression studies are undertaken to determine
the genomic effects of estrogen. Meta-analysis of such experiments may yield even
greater insight into the actions of estrogen, by comparing its effects across cell types.
51.2 Issues in Gene Expression Analysis
Multiple types of genome-scale, high-throughput data are publicly available through
the Internet via central repositories of data such as the Gene Expression Omnibus
(GEO) at the National Center for Biotechnology Information (NCBI) (Barrett et al.,
2013) and ArrayExpress at the European Bioinformatics Institute (EBI) (Parkinson
et al., 2007). The majority of these are gene expression (microarray) data. Analysis
of these data sources allows identification of co-regulated genes as well as temporal
shifts in gene expression. Also available is information from work on non-genomic
scales. Many databases, including Gene Ontology (GO), the Kyoto Encyclopedia of
Genes and Genomes (KEGG), etc., provide functional annotation data, which can be
used to inform on the potential biological meaning of other empirical data.
Regardless of the type of data being analyzed, this approach is limited by sev-
eral aspects of the microarray data itself, including but not limited to the (usually)
small number of samples in the gene expression experiments and the relatively high
noise of these experiments. Meta-analysis provides a means to increase the power of
these experiments. Other problems with microarray data include the accuracy of an-
notations (microarrays report expression values for particular probes, which must be
accurately mapped to genes to be useful), and the issue of redundant probes (multiple
probes that map to the same gene, but do not always give concordant results). One
potential reason for this is alternative splicing, where different probes hybridize to
different transcripts, or subsets of transcripts. Discordance among redundant probes
could indicate differential expression of different splice variants in response to the
perturbation being studied, information which could prove important in elucidating
the biological meaning of the results.
In this work, I present methods for dealing with both of these issues. In Chapter
2, I present an algorithm entitled “Statistical Consolidation of Redundant Expression
6Measures” (SCOREM), which consolidates concordant probes and identifies discor-
dant probes. In Chapter 3, I present another methodology, the “Global Re-annotation
and Scoring Pipeline for Expression Microarrays” (GRASPEM), for assuring the ac-
curacy of probe annotations. In Chapter 4, I utilize these two tools to perform the
meta-analysis of gene expression data for estrogen regulation, on 110 experiments
representing 19 cell types, and present the results, along with their implications for
understanding the role of estrogen in health and disease.
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8Chapter 2
SCOREM: Statistical Consolidation of
Redundant Expression Measures
2.1 Introduction
The Gene Expression Omnibus (GEO) database at NCBI is an extensive repository
of publicly available, genomic-scale data, including gene expression data. The most
common platforms in GEO are Affymetrix GeneChipr arrays (http://www.ncbi.
nlm.nih.gov/geo). One significant issue with analyzing this type of data is that,
for any given gene, a GeneChipr may contain more than one probe set designed to
hybridize to the transcript(s) for that gene. In many gene expression studies, a gene is
stated to be differentially expressed if any one of its representative probe sets reports
differential expression, without regard for the other probe sets. Ideally, a group of
probe sets representing the same gene will always behave concordantly, i.e., report
similar measures of differential expression. However, this is not always the case. One
potential reason for this is alternative splicing, where different probes hybridize to
different transcripts, or subsets of transcripts. Discordance among redundant probes
could indicate differential expression of different splice variants in response to the
perturbation being studied, information which could prove important in elucidating
the biological meaning of the results. In order to obtain the maximum and most
accurate information possible, therefore, redundant probe sets must be addressed.
Various approaches for dealing with redundant measures of gene expression have
9been proposed, from na¨ıve to elaborate. Na¨ıve approaches include choosing the
probe set with the highest variance (Falcon and Gentleman, 2007) or the best p-
value (Mieczkowski et al., 2010), or simply accepting an average value of the majority
of probe sets. More elaborate methods make use of statistical tests to analyze the
agreement between probe sets (Jaksik et al., 2009; Li et al., 2008). Another type of
methodology is to reannotate all uniquely assignable probes based on sequence align-
ment to a given gene (Dai, 2005; Ferrari et al., 2007; Harbig et al., 2005) or specific
transcript sequence (Cui et al., 2009; Lu et al., 2007; Yu et al., 2007) into one gene-
or transcript-specific probe set. Each of these approaches has its limitations. In order
to overcome those limitations and to take full advantage of all the data available from
a given experiment, I have developed the SCOREM algorithm.
The SCOREM algorithm utilizes Kendall’s W coefficient of concordance, con-
verts the results to an adjacency matrix, and then performs a search for connected
components (subgraphs) to identify concordant and discordant groups of probe sets.
We then use sequence alignment to form biological interpretations of discordant ob-
servations. The SCOREM algorithm improves the interpretation of redundant gene
expression measures both by adding statistical confidence to concordant measures,
yielding improved detection of differential expression and functional enrichment com-
pared to other methods, and by finding meaningful biological reasons (including the
prediction of novel alternate RNA isoforms) for discordant measures, something no
statistics-only or sequence-only method can deliver. Although the remainder of this
chapter refers only to Affymetrix microarrays, the same issue of redundant probe
sets also exists for other gene expression platforms, and the SCOREM algorithm is
inherently applicable to those as well.
10
2.2 Materials and Methods
2.2.1 Data sources and processing
Eight sets of data collected on four different Affymetrix GeneChipr arrays were used
in this study; five are publicly available through NCBI’s GEO website (Table 2.1).
Raw data (where available) were normalized using the R package gcrma (Wu et al.,
2004). Filtering was performed with genefilter (Gentleman et al., 2004), and fold
change (m) and significance (p) were calculated with eBayes in the limma package
(Smyth, 2004). Generally, statistical significance is determined using hard cutoffs,
e.g., a value of m greater than 2 with p better than 0.01. Here, I have implemented
a sliding scale for fold-change and significance cutoffs: the critical value for p is α,
α = 0.01 when |m| = 1; α increases up to pmax (e.g., 0.05) when |m| > 1 and decreases
when |m| < 1. The critical value for p for any given value of m is given by a sigmoid
function, similar to that described by Zhang and Horvath (2005). This sliding scale
can be utilized with or without prior p-value adjustments, such as false discovery rate
(FDR) correction (Benjamini and Hochberg, 1995). The analyses of the data sets
specified were completed with and without FDR correction. Correction with an FDR
of .05, however, can be more or less stringent than using a hard cutoff of p < .01,
depending on the sample. The use of FDR correction is further discussed in the
context of consolidation of concordant probe sets.
The analyses discussed below were carried out in R, using Bioconductor annotation
packages Mouse4302.db version 2.5, org.Mm.eg.db version 2.5, in Bioconductor release
2.8 (Gentleman et al., 2004).
2.2.2 Measurement of concordance
Kendall’s W, or Kendall’s coefficient of concordance, is a statistical method used to
measure inter-rater reliability (Kendall and Smith, 1939). Originally devised for sub-
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jective human observations in psychological studies, it has been used for the analysis
of biological data such as species associations in community ecology (Legendre, 2005).
Unlike other tests of concordance, Kendall’s W does not consider absolute values of
ratings, but overall ordering, as it is a rank-sum method based on Spearman’s ρ cor-
relation coefficient. When applied to a group of probe sets, a significant value of W
(as defined below) indicates a high level of concordance across a group of probe sets.
Groups with a value below the critical value are discordant.
Kendall’s W is calculated from the mean of all pair-wise Spearman’s coefficients
as follows (Kendall and Smith, 1939):
W =
(m− 1) ρ¯+ 1
k
(2.1)
where k is the number of judges (probe sets), the binomial coefficient
(
k
2
)
(“k choose
2”) is the number of pairs of judges, and ρ is the mean Spearman’s correlation coef-
ficient. It can further be seen that
ρ¯ =
∑
i
ρi(
k
2
) = 2
∑
i
ρi
k (k − 1) (2.2)
which when substituted into Equation 2.1 gives
W =
2
∑
i
ρi + k
k2
(2.3)
The significance of an individual value of ρ is determined using the Student’s t test
for significance with n− 2 degrees of freedom, where n is the number of observations
(arrays) (Press et al., 1992).
t = ρ
√
n− 2
1− ρ2 (2.4)
A critical value (cutoff) for ρ is calculated by rearranging the terms of this equa-
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tion, using an appropriate critical value for t (e.g., t < 0.01).
ρcrit =
√
t2crit
t2crit + n− 2
(2.5)
The critical value for W is then calculated as half the distance between ρcrit and 1
(a perfect correlation), making the W cutoff more stringent than that for an individual
ρ.
Wcrit =
ρcrit + 1
2
(2.6)
2.2.3 Detection of concordant subgroups
If the entire group’s W does not meet the cutoff Wcrit, a search for concordant subsets
within the group (subgroups) is performed. It is useful to note at this point that
Equation 2.3, from the rearrangement of Equation 2.1, is the same as taking the
mean of the symmetric matrix of pairwise coefficients. This matrix is then converted
into a matrix of true/false values, based on each ρ > ρcrit (Figure 2·3. This creates an
adjacency matrix for an undirected graph, reducing the problem of finding concordant
subgroups to that of finding connected components within the graph (Figure 2·5 (g)).
If a group is insufficiently concordant (connected under ρ > ρcrit but W < Wcrit), a
recursive search for concordant subgroups is performed.
2.2.4 Consolidation of concordant groups
When concordant groups or subgroups are found, a combined p-value can be obtained
by performing Fisher’s method (Equation 2.7) and obtaining the p-value for the
resulting χ2 value (Fisher, 1925). The individual p-values being combined are those
generated by eBayes (Smyth, 2004) for each probe set within the group.
χ2 = −2
∑
i
log (pi) (2.7)
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Fisher’s method is intended for independent measurements (Fisher, 1925). Due to
the design and experimental protocol under which the gene expression arrays are per-
formed, redundant probe sets can indeed be considered independent measures. The
standard Affymetrix sample preparation protocol calls for fragmentation of RNA (re-
sulting fragments are 35-200 bases long), therefore the pool of fragments hybridizing
to a given probe set is distinct and independent from that hybridizing to another.
For cases in which there are redundant probe sets for the same gene, some represent
uniquely processed transcripts; in theses cases hybridization is clearly independent.
However, even when probe sets represent the same transcript, there is minimal over-
lap between regions covered by those probe sets: the average overlap is 2-3%, with the
majority (80-85%) having no overlap at all. Thus, Fisher’s method is an appropriate
choice.
Finally, each group or subgroup is given a new annotation that indicates which
probe sets are included, and the total size of the group, e.g., for the gene with Entrez
Gene identifier 99999, new annotations 99999.1 2 3.5, 99999.4.5, and 99999.5.5 indi-
cate that probe sets 1, 2, and 3 out of 5 have been consolidated, while 4 and 5 have
been left as individual values. When there is more than one final value for a given
gene, a post-hoc analysis is performed, to determine which value(s) makes the most
sense, biologically speaking, to use. When necessary, probe sequences were aligned to
the most current version of their annotated RefSeq transcripts and gene exon tables
downloaded from NCBI (Pruitt et al., 2012). When probe sets failed to align to the
NCBI transcript sequences, further analysis was performed using the UCSC BLAT
website (Kent, 2002; Hsu et al., 2006).
2.2.5 R software package SCOREM
All the programs needed to carry out this analysis have been included in an R software
package, available for download from the NAR website (http://nar.oxfordjournals
14
.org/content/40/6/e46/suppl/DC1). Requirements are a normalized Expression-
Set object (as, for example, produced by gcrma) and an MArrayLM object with p
values, such as produced by eBayes. Appropriate annotation packages must also be
available. The SCOREM package includes methods for determination of concordance,
consolidation of concordant groups, and determination of differential expression, as
well as detection of discordant groups remaining after consolidation. Further analysis
can be performed using UCSC BLAT website or the standalone BLAT server pack-
age available for download (Kent, 2002). Output of the BLAT software (.psl files)
can be visualized on the UCSC Genome Browser website, or the Integrated Genome
Browser application. Since transcript annotations change on a daily basis, alignment
and visualization of probe sets of interest can be repeated as needed.
2.3 Results
2.3.1 Redundant probe sets on Affymetrix arrays
The three most common platforms in GEO are the Affymetrix Human Genome U133
Plus 2.0, the Human Genome U133A and the Mouse Genome 430 2.0 GeneChipr
arrays. On any of these arrays, a gene may be represented by one or more probe
sets. For instance, the U133 Plus 2.0 array averages 2.8 probe sets per gene (54,675
probe sets representing 19,621 genes), while the smaller 133A array averages 1.8
probe sets per gene. Overall, about half of all genes are represented by more than one
probe set; a few are represented by ten or more probe sets (Figure 2·1). Ideally, all
the probe sets for a gene would hybridize concordantly, which would provide added
confidence to the behavior being observed. However, on occasion some groups of
probe sets instead behave discordantly, for a variety of reasons: cross-hybridization
to another transcript, misannotation, or alternate-transcript-specific binding (which
may also be cell type-specific). Such groups of discordant probe sets must be identified
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and analyzed further, to determine the mostly likely signal for that condition in the
biological samples.
Several approaches for resolving the issue of different results from supposedly
analogous probe sets have been proposed. The simplest approaches for dealing with
redundant probe sets do not examine their relative behaviors, but instead employ
na¨ıve methods such as choosing the probe set with the highest variance (Falcon and
Gentleman, 2007), choosing the one with the best p-value (Mieczkowski et al., 2010),
or taking a “majority rules” approach. Other approaches use statistical tests to
analyze the level of agreement among the data. Jaksik et al. (2009) use Dixon’s
Q test to detect probe sets that are statistical outliers, having significantly higher
or lower hybridization levels than the rest, but they do not examine the level of
agreement in behavior across conditions. Li et al. (2008) use ANOVA to attempt
to distinguish probe sets that behave concordantly from those that do not. Their
analysis, however, takes an all-or-none approach, ignoring the possibility that some
subset of the probe sets might be in agreement. Other groups have implemented a
sequence-based approach to redefine the probe sets on the Affymetrix GeneChipr
arrays in order to create a one-to-one mapping of probe sets to genes (Dai, 2005;
Ferrari et al., 2007; Harbig et al., 2005) or transcripts (Cui et al., 2009; Lu et al.,
2007). Each of these approaches has its advantage and its limitations, the latter of
which the SCOREM algorithm is designed to overcome.
2.3.2 Statistical consolidation of redundant expression measures
A typical microarray analysis involves pre-processing the raw data from .CEL files,
using linear modeling to fit the samples to conditions, and determining fold change
(m-value) between conditions for each probe set (Figure 2·2a). Optionally, filtering
may be performed to remove probe sets reporting extremely low expression or vari-
ability. This step is required with the consolidation approach in order to remove
16
probe sets with zero variance, which cannot be included in correlation calculations.
Additionally, confidence levels (p-values) are generated for every m-value, and cutoffs
may be applied to the m- and p-values to extract a list of genes that are statisti-
cally differentially expressed (Methods). In this analysis, I add two additional steps
(Figure 2·2b). First, the processed data are analyzed for concordance of gene groups.
Where groups are not in concordance, they are annotated into concordant subgroups
(or individually, as warranted). Second, after the m- and p-values are calculated,
concordant groups/subgroups are consolidated to one pair of values.
Concordance is measured with Kendall’s W test (Kendall and Smith, 1939). When
a group is found not to be concordant, the group is searched for subgroups that are
concordant. Probe sets are then reannotated with their new group ids - all the same
for groups with complete concordance, or distinct ids for two or more subgroups. In
the most discordant case, each probe set remains as a separate value. When the anal-
ysis is complete, each consolidated (sub)group will have a single m-value (fold change)
with a corresponding p-value for each comparison performed in the experiment (e.g.,
treatment vs. control). To determine m for a concordant (sub)group, the individual
m-values are averaged. P-values are combined using Fisher’s method (Fisher, 1925).
The resulting values are tested for statistical significance as described in Methods.
The final list of differentially expressed genes can then be used for further analysis,
such as enrichment of functional categories. In order to understand the biological
basis for any probe set groups that were not fully consolidated, they are examined
further by sequence alignment to the current version of the transcript or gene.
2.3.3 Application of SCOREM
In all, I applied the SCOREM algorithm to eight data sets, on four different Affymetrix
arrays (Table 2.1). On average, 41% (range 6-56%) of the redundant probe sets were
able to be completely consolidated, 19% were partially consolidated, and approxi-
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mately 40% were not able to be consolidated at all (Table 2.2). The genes in the
latter two categories are examined further, to examine potential reasons for the dis-
cordant behaviors of their probe sets.
In comparing any two conditions A and B (e.g., drug treatment vs. control, mutant
vs. wild type, or tumor vs. normal tissue), a given probe set or group of probe sets
can be (a) higher in A than in B, (b) lower in A than in B, or (c) the same in A
and B (no change). Thus, types of discordant behavior I can examine include when
one probe set or subgroup reports differential expression (either higher or lower) in
a given condition while another probe set or subgroup is unchanged. Another occurs
when two groups report differential expression in opposite directions. A third can
be considered to occur when both groups report differential expression, in the same
direction, but of very different magnitudes (e.g., two-fold vs. eight-fold increases). In
an experiment with more than two conditions (e.g., a time course, or testing multiple
different drugs), discordant subgroups can exhibit one or more of these behaviors.
Table 2.3 summarizes, for each data set, how many instances of the first two types
of discordant behaviors exist among the genes reported to have changing expression
levels in more than one subgroup of probe sets.
2.3.4 Post-hoc analysis and the detection of differential processing
Potential reasons for discordant behavior among probe sets representing the same
gene include multiple RNA isoforms for the gene, misannotation of probe sets, and
cross-hybridization of multiple mRNAs to a single probe set. Multiple RNA isoforms
can be generated via alternative splice sites, polyadenylation sites, and/or promoters.
To determine whether probe set inconsistencies in hybridization levels could be due to
biologically significant differences, the probes in each probe set or group are mapped
to the sequences for all annotated transcript variants of that gene.
Through such mapping we have also validated the relevance of the SCOREM
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approach, as many of the discordancies can be attributed to known cases of alternative
RNA transcripts. In the data sets analyzed, there were 77 cases in which discordantly
expressed subgroups for the same gene were expressed in opposite directions (Table
2.3, final column). The 76 genes (one is discordant in two data sets) are represented
on the arrays by 298 total probe sets (199 after gene filtering). For 26 of these genes,
probe sets differentially mapping to distinct, known RNA isoforms can account for the
discrepancy (see (Schneider et al., 2012), Supplementary Data); the alternate RNA
isoforms are annotated in RefSeq (Pruitt et al., 2012) for fifteen of these genes and in
the UCSC Genome Browser (Hsu et al., 2006) for an additional eleven cases. These
reflect all types of alternative transcript formation: alternative splicing (fifteen genes),
alternative polyadenylation (nine genes), and alternative promoters (two genes).
One example where discordant probe sets map to distinct transcripts occurs in
Shprh (encoding SNF2 histone linker PHD RING helicase). This gene is represented
by four probe sets on the Affymetrix Mouse Genome 430 2.0 array. In the GSE4051
data set, SCOREM measures the correlation coefficient W to be 0.42, not signifi-
cantly concordant. However, when the discordant subgroups are analyzed, it is clear
that two of the probe sets reflect discordant expression values; hybridization to one
(1452261 at) increases when that to the other (1457327 at) decreases. There are two
known RefSeq transcripts for Shprh, NM 172937 and NM 001077707 (Figure 2·4a);
due to differential splicing these transcripts contain distinct 3′ untranslated regions
(UTR). Aligning the probe sequences to the genomic sequence of Shprh reveals that
each of the discordant probe sets maps exclusively to only one of the two different
isoforms. Thus, it is straightforward to interpret that under conditions of this experi-
ment (in the mouse retina in response to a knockout of the Nrl gene), when expression
of the Shprh transcript NM 001077707 increases, expression of transcript NM 172397
decreases. Thus, the SCOREM analysis uncovers novel biological information regard-
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ing expression of this gene.
For an additional 35 genes in which discordantly expressed subgroups were ex-
pressed in opposite directions, known isoforms did not distinguish behavior between
probe sets. Instead, mapping of the probe sets suggest novel RNA isoforms. The
simplest interpretations of various observed scenarios include: (1) when discordant
subgroups of probe sets map to distinct coding exons, we propose novel alterna-
tively spliced variant(s); (2) when a discordant subgroup maps to an intron between
coding exons, we propose alternate isoforms containing novel exons; (3) when discor-
dant subgroups map to distinct regions within the known 3′UTR or when some map
downstream of the known 3′UTR, we propose alternative polyadenylation; (4) when a
discordant subgroup maps either to regions upstream of the identified promoter or to
an intron prior to the encoded translational initiation codon, we propose an alterna-
tive transcription start site (promoter). Other interpretations of novel RNA isoforms
for the respective genes are clearly possible. The analysis does not pinpoint the al-
ternate RNA isoform, but it does suggest that more than the known RNAs are being
expressed, for subsequent experimental exploration. Finally, it is possible (depending
on the source of RNA used in the experiments) that signal from probe sets (especially
ones in introns) reflect either partially processed RNA or RNAs unconnected to the
gene in question (e.g. noncoding RNAs overlapping the genomic region).
Examples of three categories of genes containing discordant probe sets that can-
not be explained by known RNA isoforms are shown in Figures 2·4b-d. Dpysl2 is
represented by discordant probe sets that both map (partially or completely) in the 3
untranslated region (Figure 2·4b); this is an example of potential alternate polyadeny-
lation sites in the terminal exon. For Scmh1, one discordant probe set maps in the
intron upstream of the first coding exon (Figure 2·4c); this is predicted to reflect an
alternate promoter, most likely mapping within the annotated intron 4. For Mllt10,
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there are two probe sets mapping to annotated introns 3 and 4, respectively, where
their expression levels change in opposite directions (Figure 2·4d). This scenario
suggests alternative splicing, presumably including novel coding exons within the
annotated introns 3 and/or 4.
Finally, sixteen of the 77 cases could not be explained by the existence of alternate
RNA isoforms. For these, the use of BLAT (Kent, 2002) to align the individual probe
sequences against the entire genome can reveal whether some of the probes do not
appropriately represent the gene in question (misannotation) or represent more than
one gene (cross-hybridization). For eight of these genes, at least one of the probe sets
is misannotated (including probe sets that map to the non-coding strand, or to non-
coding RNAs overlapping the given gene). Two genes are represented by a probe set
that has the potential to cross-hybridize to another gene on a separate chromosome.
Finally, six genes do not include annotated exon information, and cannot therefore
be assessed.
Overall, the ability to identify and map the locations of probe sets that reflect
discordant expression patterns expands and clarifies the information gleaned from
analyzing gene expression data. As a validation that SCOREM appropriately sep-
arates probe sets into discordant subgroups, over a third of the more severely dis-
cordant subgroups can be explained by distinct, known RNA isoforms. For these
genes, the discordant expression behavior can add valuable biological insights. In
approximately 45% of the cases, our analysis suggests novel RNA isoforms that are
differentially regulated, thus generating hypotheses to be tested for genes of inter-
est. Finally, by invalidating probe sets in the remaining 20% of the discordant cases,
incorrect data can be excluded from further consideration.
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2.3.5 Detection of tissue-specific behaviors
Since SCOREM performs a new analysis of concordance/discordance in each exper-
iment, the results for any given group of probe sets may differ from experiment to
experiment. For instance, this could reflect tissue- or cell type-specific expression of
alternate variants. An interesting case in point is that of Rbm39 (Entrez Gene ID
170791). This gene is represented by ten different probe sets, according the annota-
tion supplied by Affymetrix. In the analysis of the GSE9371 data sets, the ten probe
sets were not concordant (W=0.47) (Figure 2·5a), but two subgroups were highly
concordant (Figure 2·5b-c). If the na¨ıve approach of “majority rules” had been ap-
plied, the first group (Figure 2·5b) with five probe sets would have been taken as the
representative value. However, mapping probes to the transcript sequence indicates
that only the smaller subgroup of two probe sets (Figure 2·5c) maps to the anno-
tated (exonic) transcript sequence (Figure 2·5d). The larger subgroup maps instead
to intronic regions of the gene. Whether these represent a separate transcript (e.g.,
non-coding RNA, overlapping gene) or unannotated alternate exons requires further
investigation. Most importantly, Figure 2·5e-i shows that the clustering of probe sets
is different in different experiments. In particular, note that probe sets 2 and 3 do not
always behave concordantly, and in one case all ten probe sets act in concert. Using
the standard analysis from Figure 2·2a, these experiment-dependent differences would
not be discerned. Thus, the method described here is sufficiently flexible to provide
important additional nuances in understanding the differential RNA processing.
We have examined the possibility that some genes would always have discordant
probe sets, and have found that not to be the case. In the eight data sets examined,
only one gene (WD repeat domain 33 (Wdr33), EntrezGene 74320) was discordant
in more than one set (GSE4051 and Inguinal Fat). However, even in this case, the
seven probe sets representing this gene were not grouped in the same manner, and so
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were discordant in different ways. This again leads to the conclusion that patterns
of concordance and discordance cannot be assumed to be replicable across data sets.
It is also important to note that these data were generated by different labs under
different conditions, and the effects of differences in sample preparation should also
be considered. For instance, not all samples may have been prepared using poly-A
selection (usually employed to select for fully processed mRNA transcripts and avoid
partially processed, i.e., not fully spliced, forms). Therefore, some of the discrepancies
may be due to the presence of incomplete transcripts or unspliced transcripts in some
data sets and not others.
2.4 Discussion
The SCOREM algorithm is a novel approach to gene expression analysis, making use
of Kendall’s coefficient of concordance to determine the level of agreement (concor-
dance) among multiple probe sets representing the same gene in a gene expression
experiment. While other methods have been proposed to resolve the issue of so-called
redundant probe sets, SCOREM is the only one that also provides information about
differential RNA processing, even when no known alternate transcripts exist, and thus
can reveal tissue- or cell-specific expression patterns. At the same time, it yields ex-
pression measures with increased statistical confidence, leading to further statistical
confidence in secondary analyses such as functional enrichment analysis.
SCOREM is evaluated here in comparison with a standard (non-consolidating)
approach to expression analysis, as well as two other methods for consolidation. Li
et al. (2008) use ANOVA to analyze agreement between multiple probe sets, while
Dai (2005) use sequence alignment information to create composite probe sets. We
evaluate each method for its ability to detect differentially expressed genes and the
statistical confidence of subsequent functional enrichment analyses (measured as the
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average p-value of the top 20 categories detected as enriched by GOstats (Falcon and
Gentleman, 2007)).
2.4.1 Comparison with a standard approach
Overall, SCOREM consistently calls more differentially expressed genes than the
standard method (Table 2.4a). This includes more genes in each statistically over-
represented functional category, resulting in better p-values of the top categories
identified by GOstats (Falcon and Gentleman, 2007) (Table 2.4b).
For example, our previous studies investigated the role of estrogen and estrogen
receptors (ER) α and β in regulating gene expression in vascular tissue (GSE9371)
(O’Lone et al., 2007). This study found that estrogen/ERβ was responsible for down-
regulation of a number of nuclear-encoded genes in the mitochondrial respiratory
chain. Using a standard analysis, seventeen genes in the oxidative phosphorylation
pathway (KEGG:00190) were identified that had at least one probe set reporting
differential expression. Using SCOREM, the list was extended to 26 genes (fourteen
from the original list plus twelve new genes, Table 2.6); consequently, the p-value for
the statistical significance of this pathway went from 1.9× 10−04 to 1.8× 10−7.
Since the standard approach makes no attempt to consolidate redundant probe
sets, the resulting list of differentially expressed genes typically includes values from
redundant probe sets, with no mention of other probe sets corresponding to these
genes. There were a total of over 3000 redundant measures in the lists for the eight
data sets generated by the standard method, compared to only 334 remaining redun-
dant measures for SCOREM.
2.4.2 Comparison with a statistical approach
The approach developed by Li et al. (2008) utilizes ANOVA with the intent of dis-
tinguishing between the effects of discordancy on expression measures and true ex-
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perimental effects. This analysis takes an all-or-none approach, in which all probe
sets that are in agreement are consolidated while probe sets not in agreement are all
treated as separate measurements, ignoring the possibility that some subset might be
in agreement and that this could be the source of valuable information about the gene
in question. However, as SCOREM demonstrates, in the majority of cases multiple
concordant subgroups can be delineated (Table 2.2, Consolidation). For example,
the ANOVA approach of Li et al. (2008) treats all probe sets as separate signals for
Lman1, even though three out of five probe sets are hybridizing concordantly and
can be consolidated into one statistically significant increasing value, while a fourth
is decreasing . Finally, when directly compared, SCOREM finds more differentially
expressed genes and shows better enrichment of experimentally relevant functional
categories than the ANOVA approach (Table 2.4).
2.4.3 Comparison with a custom CDF approach
Dai (2005) use a sequence-based approach to generate a custom Chip Definition File
(custom CDF) that redefines the probe sets on the Affymetrix GeneChipr arrays to
generate a single probe set per gene. Probes that match more than one transcript (or
no annotated transcripts) are removed entirely; the remainder is consolidated into one
probe set. As pointed out in (de Leeuw et al., 2008), typically more than half of the
data from hybridization to an array is eliminated. The number of genes represented
by the final probe sets is reduced as well (Table 2.5). While de Leeuw et al. (2008)
salvage these lost probe sets by creating hybrid CDFs and annotating “less reliable
probe-sets,” SCOREM takes the approach of examining probe set behavior in each
data set, and annotating the reliability of those whose behavior is inconsistent with
the more reliable of its siblings. It is not surprising, given the loss of data in the
custom CDF approach, that SCOREM finds more differentially expressed genes and
shows greater significance of enriched functional categories (Table 2.4).
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The custom CDF approach has been favorably reviewed (Sandberg and Larsson,
2007) and is currently is use by others, e.g., (Carroll et al., 2006). However, it does
have a number of limitations. First, it can only be applied to raw data (Figure 2a);
while gene expression data in GEO are increasingly available in raw format, many
data sets are still only available in pre-processed form (Larsson and Sandberg, 2006).
Second, as a result of eliminating so many probes, the redefined probe sets vary
widely in size, from as few as three to over one hundred probes, instead of the origi-
nal eleven, thus in any given probe set there may be too few probes left to generate
a statistically significant result. For example, analysis of the GSE9371 data set with
SCOREM indicates that all 3 probe sets (33 probes total) for Cox7a2l (Entrez Gene
20463) behave in a highly similar fashion, leading to a highly significant combined
expression change (Table 2.6). However, the BrainArray custom CDF file eliminates
all but 6 of the 33 probes, and consequently does not consider the results for this
gene to be significant. Third, the new probe set definitions are based on the current
annotated genomic sequences, which are certain to change, especially as more splice
variants are found. As a result, the entire analysis must be repeated each time a new
version of the custom CDF is released, requiring periodic downloads of large annota-
tion packages. Fourth, this approach eliminates non-annotated sequences, producing
a bias towards well-understood transcripts, and limits the ability of researchers to
identify unannotated transcripts that nevertheless may be of critical importance in a
particular study. Finally, this approach is based solely on sequence and not at all on
behavior, with the same probes being consolidated for each gene expression experi-
ment. However, our method reveals that redundant probe sets can show independent
behaviors in different conditions or tissue or cell types.
As an example of the effect of combining probe sets based only on sequence, the
gene Shprh is represented by four probe sets on the Affymetrix Mouse 430 2.0 array.
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The BrainArray custom CDF retains and combines 35 of the 44 probes for these
probe sets. SCOREM, however, reveals that two of the probe sets are not hybridizing
at all, while the other two uniquely map to (and hybridize with) each of two different
known isoforms (Figure 2·4a). As a result, the BrainArray analysis concludes this
gene is not differentially expressed, while SCOREM reveals that both isoforms are,
but in different directions.
2.4.4 Further applications
Although this chapter has only shown the results of applying SCOREM to Affymetrix
microarray data, SCOREM is platform-independent and can be applied to any type of
data containing redundant measures where a single value is desired. All that is needed
is an ExpressionSet object containing normalized data and an MArrayLM object with
p-values, such as produced by eBayes (Smyth, 2004). In the case of the discordant
behaviors where one probe set or subgroup is reporting differentially expression and
other subgroup(s) for that gene are not, or where the groups are reporting differential
expression of different magnitudes (Table 2.2, columns a and b), the post-hoc analysis
described in Results can also be applied. Finally, results of a BLAT analysis can be
downloaded from the UCSC website, and visualized with a tool such as the Integrated
Genome Browser (IGB) (Nicol et al., 2009). Therefore, SCOREM can be applied to
any type of data and make sense of any type of discordant behavior present in that
data.
2.5 Conclusions
The SCOREM algorithm has several advantages, both technical and biological, over
the other methods examined. Its technical advantages include that: (1) it is applicable
to raw data (.CEL) or preprocessed data; (2) its basic analysis does not change,
even when sequences are re-annotated, therefore only the post-hoc analysis must be
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repeated when new information becomes available; (3) probe sets that do not map to
currently known coding sequences are retained for future analysis, not discarded; (4)
it does not require downloading of multiple, large annotation packages from external
sources, instead utilizing the latest annotation obtained directly from NCBI; and (5)
it is applicable to any type of expression data with redundant expression measures,
regardless of platform.
SCOREM also has several key biological advantages over statistical-only or sequencing-
only approaches, including that: (1) it identifies differential RNA processing of known
isoforms, and it detects potential novel isoforms; (2) it makes no a priori assumptions
that behavior will be the same across experiments, allowing the detection of tissue- or
cell-specific differential processing; and (3) when redundant probe sets behave concor-
dantly, it provides greater statistical confidence in measuring differential expression
and in subsequent functional enrichment analyses.
By assessing redundant probe sets based on their behavior, not just their sequence,
we achieve an increase in statistical power for concordant sets, and an opportunity for
further analysis for discordant sets. Therefore, by utilizing the SCOREM approach,
we obtain results with greater statistical confidence in the determination of differential
expression and subsequent analysis of functional enrichment, and gain additional
information about tissue-and isoform-specific behavior of genes.
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Table 2.1: Data used in evaluating the SCOREM algorithm. Source
(Raw) indicates the source of the data, and whether or not raw data
(.CEL files) or only preprocessed data were available.
Data Set Tissue
Type
Conditions Platform Source
(Raw)
# of
Samples
GSE3678 Thyroid Tumor vs. normal hgu133plus2 GEO
(yes)
14
GSE4051
(Akimoto
et al., 2006)
Retina Nrl-KO vs.WT at 5
developmental times
mouse4302 GEO
(yes)
39
GSE4799
(Oatley
et al., 2006)
Sperma-
togonial
stem
cells
Growth factor at 3
times vs. withdrawal
and baseline
mouse4302 GEO
(no)
15
GSE9371
(O’Lone
et al., 2007)
Aorta Estrogen vs. placebo
in WT, ERα-, and
ERβ-knockouts
mouse4302 GEO
(yes)
22
BrCa*
(Chang et al.,
2006; Frasor
et al., 2006;
Chang et al.,
2008)
MCF7
cell line
Estrogen vs. placebo
at 2 time points
hgu133a GEO
(no)
26
VSMC
(Schnoes
et al., 2008)
Aorta Estrogen vs. placebo
at 3 time points
mouse430a2 authors
(yes)
18
GonFat
(Grove et al.,
2010)
Gonadal
fat
Female vs. male and
female vs. OVX
mouse4302 authors
(yes)
21
IngFat
(Grove et al.,
2010)
Inguinal
fat
Female vs. male and
female vs. OVX
mouse4302 authors
(yes)
21
* This data set consists of similarly treated samples from GEO series GSE4006, GSE4025, and
GSE9936.
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Table 2.3: Characterization of differentially expressed groups repre-
senting differentially expressed genes from eight gene expression data
sets. The columns under “Multiple Subgroups” refer to results pro-
ducing discordant groups where (a) one is changing and the other is
not; (b) both are changing in the same direction, but with different
magnitudes; and (c) one is increasing while the other is decreasing.
Number of Genes Represented By:
Total A Multiple Subgroups
Number Single (a) Yes (b) Small (c) Down
Data Set of Groups Group vs. No vs. Large vs. Up
GSE3678 1430 1383 0 5 0
GSE4051 4006 3656 126 24 13
GSE4799 5122 4239 348 16 43
GSE9371 1593 1509 32 3 2
BrCa 947 915 5 1 0
VSMC 451 447 1 0 0
GonFat 4559 4449 14 3 13
IngFat 3049 2933 32 2 6
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Table 2.4: Comparison of SCOREM with other methods in terms
of detection of differential expression and functional enrichment. The
ANOVA columns contain (a) the number of differentially expressed
genes and (b) the average p-values of top 3 or 5 GO categories, taken
from (Li et al., 2008). In the Custom CDF columns, NA indicates data
sets with no raw data available, where the custom CDF approach could
not be applied. In (b), “none” indicates fewer than five GO categories
with any overrepresentation.
(a) Number of genes called differentially expressed.
Data Set
Standard
(with FDR)
ANOVA Custom CDF
SCOREM
(with FDR)
GSE3678 1026 (1064) 402 667 1405 (821)
GSE4051 2829 (2400) 313 1678 3829 (1930)
GSE4799 2146(323) 832 NA 4660 (298)
GSE9371 720 (102) NA 480 1550 (123)
BrCa 73 (1137) NA NA 931 (592)
VSMC 8 (92) NA 126 44* (53)
GonFat 1753 (6005) NA 1966 4502 (3455)
IngFat 777 (3925) NA 940 2989 (1782)
(b) Average p-value of top 20 enriched GO categories.
Data Set
Standard
(with FDR)
ANOVA Custom CDF
SCOREM
(with FDR)
GSE3678
4.5× 10−10
(1.8× 10−7) 3.5× 10
−2 2.5× 10−6 1.3× 10
−10
(5.1× 10−9)
GSE4051
6.1× 10−10
(5.1× 10−8) NA 2.0× 10
−4 1.6× 10−6
(4.9× 10−8)
GSE4799
3.6× 10−10
(5.3× 10−9) 1.2× 10
−2 NA 2.0× 10
−13
(2.8× 10−10)
GSE9371
6.1× 10−7
(3.0× 10−5) NA 8.6× 10
−6 1.8× 10−9
(9.5× 10−6)
BrCa
3.6× 10−4
(5.0× 10−5) NA NA
6.3× 10−5
(3.0× 10−5)
VSMC none (none) NA 9.8× 10−4 4.5× 10
−4
(none)
GonFat
3.2× 10−15
(2.5× 10−12) NA 1.2× 10
−9 8.3× 10−13
(1.7× 10−13)
IngFat
1.6× 10−8
(4.4× 10−9) NA 7.9× 10
−6 3.5× 10−8
(1.9× 10−8)
32
Table 2.5: Comparison of the number of probes, probe sets used, and
genes represented in Affymetrix and Brainarray custom CDF files.
Array CDF Probes Probe Sets Genes
Human U133 Plus 2.0 Affymetrix 604258 54675 19798
Custom 277789 19008 18974
Human U133A Affymetrix 247965 22283 12718
Custom 167345 12078 12065
Mouse 430 2.0 Affymetrix 496468 45101 20757
Custom 240917 17306 17289
33
Table 2.6: Oxidative phosphorylation genes detected in data set
GSE9371. Values are the number of probe sets (probes) without con-
solidation (standard method) and after consolidation, by either the
Custom CDF method or SCOREM. Yes/No indicates whether or not
that gene was called differentially expressed by at least one probe set
or consolidated group by that method.
Consolidation Method
Gene (Entrez ID) None Custom CDF SCOREM
Atp5d (66043) 2 (22) No 1 (22) Yes 1 (22) Yes
Atp5j2 (57423) 3 (33) No 1(7) No 2 (33) Yes
Atp5o (28080) 1 (11) Yes 0 (0) No 1 (11) Yes
Cox5b (12859) 6 (66) Yes 0 (0) No 1 (66) Yes
Cox7a2l (20463) 3 (33) Yes 1 (6) No 2 (33) Yes
Cox8a (12868) 2 (22) Yes 1 (19) Yes 1 (22) Yes
Cox8b (12869) 1 (11) Yes 1 (11) Yes 1 (11) Yes
Cox10 (70383) 3 (33) No 1 (14) No 3 (33) Yes
CYesc1 (66445) 1 (11) Yes 1 (10) Yes 1 (11) Yes
Ndufa3 (66091) 3 (33) No 1 (16) No 1 (33) Yes
Ndufa7 (66416) 5 (55) No 1 (13) Yes 1 (55) Yes
Ndufa8 (68375) 1 (11) No 1 (10) No 1 (11) Yes
Ndufa10 (67273) 2 (22) Yes 1 (9) No 1 (22) No
Ndufb2 (68198) 4 (44) No 1 (8) Yes 2 (44) Yes
Ndufb5 (66046) 1 (11) Yes 1 (17) Yes 1 (11) Yes
Ndufb8 (67264) 2 (22) No 1 (5) Yes 2 (22) No
Ndufb9 (66218) 3 (33) No 1 (20) No 1 (33) Yes
Ndufc1 (66377) 2 (22) Yes 1 (10) No 1 (22) Yes
Ndufs3 (68349) 1 (11) Yes 0 (0) No 1 (11) Yes
Ndufs4 (17993) 4 (44) Yes 1 (14) No 1 (44) No
Ndufs7 (75406) 2 (22) No 1 (21) No 1 (22) Yes
Ndufs8 (225887) 6 (66) Yes 1 (50) Yes 1 (66) Yes
Ndufv1 (17995) 3 (33) No 1 (30) No 1 (33) Yes
Ppa1 (67895) 1 (11) No 1 (7) No 1 (11) Yes
Sdha (66945) 4 (44) Yes 1 (22) No 2 (44) No
Sdhb (67680) 1 (11) Yes 1 (9) Yes 1 (11) Yes
Sdhd (66925) 2 (22) No 1 (18) Yes 1 (22) No
Tcirg1 (27060) 1 (11) No 1 (9) Yes 1 (11) Yes
Uqcrc1 (22273) 1 (11) Yes 1 (9) Yes 1 (11) Yes
Uqcrfs1 (66694) 1 (11) No 1 (11) Yes 1 (11) No
Uqcrq (22272) 3 (33) Yes 1 (22) Yes 1 (33) Yes
Uqcr10 (66152) 1 (11) Yes 1 (5) No 1 (11) Yes
Total Called Present 17 15 26
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Figure 2·1: Distribution of the number of probe sets per gene on the
three indicated popular Affymetrix GeneChipr arrays.
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Preprocessing
(background correction,
 CDF-based summarization 
of probes,  normalization)
Processing
List of Differentially 
Expressed Probe Sets
Are m- and p-values 
significant?
(linear modeling and
contrast fitting)
Raw Data (.CEL files)
Group probe sets
by Entrez Gene IDs
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  Expressed Genes
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Is n>1?
Is W > Wcrit?
Post-hoc Analysis
(sequence alignment)
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significant?
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Figure 2·2: Flowchart for algorithms for analyzing gene expression
data. (a) Typical Affymetrix processing. (b) SCOREM processing
with concordance testing and consolidation.
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Figure 2·4 (following page): Examples of post-hoc analysis in order
to determine causes for discordant expression patterns. Genomic DNA
is indicated as a line, with exons indicated as boxes on the line. Nu-
cleotide positions within each genes are given with zero representing the
presumed transcription start site for the indicated mRNAs. Mapping of
each probe set is color-coded for each gene. Translation start and stop
codons are indicated by arrows and asterisks, respectively. Whether
each probe set is differentially regulated in the experimental samples,
and the direction of regulation, are indicated in parentheses after each
probe set id. (a) Detection of different expression patterns in known
alternate RNA isoforms of Shprh. The probe sets reporting differential
expression correspond to exons unique to each of the known isoforms.
Expression changes are for experiment GSE4051 at the post-natal day
10 time point. (b) Identification of a possible novel isoform of the gene
Dpys12. The alternate RNA isoform could involve alternate splicing of
exons 12-14 or an alternate 3′UTR (polyadenylation site). Expression
changes are for experiment GSE4799, deprivation vs. untreated. (c)
Identification of a potential alternate promoter in Scmh1. Expression
changes are for experiment GSE4051 at the embryonic day 16 time
point. (d) Identification of potential novel coding exons in Mllt10, in
introns 3 and/or 4. Expression changes are for experiment GSE4799, 2
hours post-restoration vs. untreated.
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Shprh (268281)
SNF2 histone linker PHD RING helicase 
1430582_at (no expression)
1452261_at (up)
1457327_at (down)
1458594_at (no expression)
NM_001077707.1 (30 exons)
Gene Position (nucleotides)
NM_009955.3 (14 exons)
Dpysl2 (12934)
dihydropyrimidinase-like 2 
1433770_at  (down)
1450502_at  (up)
(a)
(b)
NM_010804.3 (23 exons)
1420869_at  (no change)
1420870_at  (no change)
1438525_at  (down)
1442070_at  (up)
Mllt10 (17354)
myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 10
(d)
0                                                 20,000                                             40,000                                            60,000
0                                                   50,000                                               100,000                                             150,000
0                                                 20,000                                            40,000                                             60,000
0                                                    40,000                                               80,000                                              120,000
       NM_013883.2 (17 exons)
NM_001159630.1 (18 exons)
Scmh1 (29871)
sex comb on midleg homolog 1
1426241_a_at  (down)
1441573_at       (up)
(c)
NM_172937.3 (28 exons)
Gene Position (nucleotides)
Gene Position (nucleotides)
Gene Position (nucleotides)
39
Figure 2·5 (following page): Graphical analysis of probe sets an-
notated as representing Rbm39 (encoding RNA binding motif pro-
tein 39) from multiple experiments performed on the Mouse 430 2.0
GeneChipr.(a-c) Expression profiles of probe sets across the 22 sam-
ples in the GSE9371 data set; W indicates level of concordance. (a)
All ten probe sets; W shows lack of concordance. A dotted line shows
a probe set removed by gene filtering (for very low expression or very
low variance) and therefore not included in the calculation of W. (b)
The largest subgroup includes probe sets 4, 6, 7, 9, and 10; W shows
high concordance. (c) The second subgroup includes probe sets 2 and
3; W shows high concordance. (d) Mapping of the ten probe sets to
the genomic sequence of Rbm39 and the exons of its only known tran-
script. Probes mapped above the line map to the coding (negative)
strand, those below the line map to the non-coding (positive) strand.
(e-i) Connected subgraphs indicating groups of concordant probe sets
in five different experiments. In parentheses are the number of sam-
ples in each data set (n) and the critical value for W for a data set
of that size. W is given for each group as a whole (bottom) and for
each concordant subgroup (below each subgroup). Filled circles indi-
cate statistically significant differential expression in that experiment.
A dotted circle indicates a probe set removed during gene filtering in
that data set.
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(a) (c)(b)
(d)
(e) GSE4051 
       (n=39, Wcrit=0.69)
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Chapter 3
GRASPEM: Global Re-Annotation and
Scoring Pipeline for Expression
Microarrays
3.1 Introduction
With the rapid increase in the amount of gene expression data being generated, public
databases such as NCBIs GEO (Barrett et al., 2013) now contain large quantities
of information that can be tapped for almost any type of study, the vast majority
of which utilize oligonucleotide-based platforms (Table 3.1). These include in situ
oligonucleotide microarrays, spotted (custom) microarrays, and bead-based arrays.
The information available from any single microarray experiment may be limited, as
experiments normally only contain a few samples each. Meta-analysis of multiple
experiments using similar treatments and conditions can lead to increased confidence
in the conclusions that can are drawn. For example, meta-analysis of breast cancer
microarray studies has previously been used to identify novel pathways common to
metastatic tumors and class-specific patterns of regulation (Thomassen et al., 2008;
Smith et al., 2008). However, meta-analysis can be limited by the lack of comparable
annotations among microarray platforms. This is further complicated by constantly
changing genome annotations which diminish the accuracy of manufacturer-supplied
annotations (Dai, 2005). Additionally, lack of transcript-specific annotations result
in probes that ostensibly map to the same gene but provide very different measures of
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differential expression (Schneider et al., 2012; Cui et al., 2009; Lu et al., 2007; Yu et al.,
2007). In order to fully harness the information provided by any experiment, first
the annotation and reliability of the probes must be examined. Once re-annotation
is complete, equivalent probes from different platforms can be compared on equal
footing to provide a more robust estimate of differential expression.
One factor affecting probe reliability is the location of the probe on the transcrip-
tome as well as the genome. For instance, probes may hybridize to more than one
place in the genome or transcriptome, or to one site that happens to coincide with two
overlapping genes. Probes designed against transcripts may span splice sites that are
not consistently spliced the same way, thus alternate splicing may render such probes
invalid at certain times and in certain conditions. Due to changing annotations, a
gene may not have the same name or Entrez Gene id as it had when the annotation
was last released.
Probes designed against ESTs may be hybridizing to sequences that are not in the
current transcriptome annotation. For instance, they may hybridize to unannotated
exons, novel poly-adenylation sites (extended 3′ ends), or novel promoter sites (5′
ends). These sequences may also represent retained introns in non-coding transcripts,
which may not truly represent the gene of interest. Therefore, by assigning scores to
probes based on their location relative known transcripts, we can give greater weight
to the expression measures from those probes that are known to map to exons, and
lower weight to those that do not.
To address these issues, I have developed a global re-annotation and scoring
pipeline for expression microarrays, or GRASPEM. GRASPEM first maps probes
to the latest genome assemblies and transcriptome annotations, then assigns each
probe a score for predicted reliability. This permits calculation of weighted expres-
sion values in a given experiment (Figure 3·1). Using a database of probe scores
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and annotations, the results of multiple experiments can then be compared, with
the weighted expression values of like probes (probes aligning to the same exons of
the same gene) combined to produce a more robust expression measure. Finally, I
have developed a visualization tool to connect probe location and score information
with weighted expression values, to facilitate cross-platform comparison of differential
expression results.
3.2 Materials and Methods
The pipeline was designed to work with any platform whose probe sequences are
available in an R package or through GEO. There are two main types of platforms:
probe-based and probe-set based. Affymetrix platforms measure gene expression via
probe sets, consisting of 11 or more individual probes (oligomers 25 bases long), gene
expression values are typically given for each probe set, and so scores and annotations
are also given in this method for each probe set. Illumina and Agilent platforms, as
well as some custom microarrays, use individual probes, each 50-60 bases long, that
are scored individually. The two main stages of the pipeline are, first, mapping
to the latest genome and transcriptome versions, and, second, scoring each probe for
predicted reliability based on uniqueness, quality, and genomic and/or transcriptomic
location. In addition, probe scores are converted to probe set scores for Affymetrix
platforms.
3.2.1 Data sources and processing
The first step in the pipeline is to map each probe sequence to the latest versions of the
genome and transcriptome. Probe sequences for each package are obtained directly
from GEO (Barrett et al., 2013), via the R package GEOquery (Davis and Meltzer,
2007). The target sequences (FASTA files of complete genome (by chromosome) and
transcriptome sequences) are downloaded from the UCSC Genome Browser (Kuhn
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et al., 2013). The probe sequences are aligned to the targets with stand-alone BLAT,
chosen for its speed and ease of incorporation into the computational pipeline (Kent,
2002). Alignment to the genome needs to be repeated only when a new assembly
is released; alignment to the transcriptome should be repeated periodically, as new
transcripts are added on a daily basis. BLAT is run against the appropriate target
sequences (genome or transcriptome) for all probes, using the suggested parameters
for short sequences (i.e., -stepSize=5 -repMatch=1000000). To avoid matching repeat
sequences, either sequences with masked repeats should be used, or the mask setting in
BLAT can be employed, however, scoring (see below) is such that any probe matching
repeated sequences will receive a score of zero regardless. For each probe sequence,
the result is limited to the best one (or more than one, when there was a tie) for each,
as determined by number of mismatches and gaps to the target sequence. Each such
alignment result is hereafter called a “hit.”
3.2.2 Gene and location annotation
Once the probes are aligned to the genome, the alignment locations are mapped to
a curated set of known genes. To prepare the database of genes, genome mapping
data for human, mouse, and rat genomes was downloaded from NCBI (International
Human Genome Sequencing Consortium, 2004; Church et al., 2009; Genome Thera-
peutics et al., 2004). Inclusion of gene locations was restricted by the following two
criteria: only genes with a location on a reference chromosome (RefSeq accession
number beginning with NC) were included, and genes annotated with locations on
more than one chromosome were removed (with the exception that for genes mapping
only to both the X and Y chromosomes, in which case the Y location was dropped).
Furthermore, gene locations were curated to eliminate ambiguities, prior to probe
alignments. For overall gene locations, when more than one possible start or end
site was given, the widest span of the gene was used, if the locations given were
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overlapping. In the case where two locations were given that did not overlap, the
gene id was relabeled with the additional of sequential numbers. The pipeline then
compares the probe alignment locations with these curated gene locations using the
R IRanges package (Pages et al., 2013). If no assignment of a probe to a gene is
initially found, the alignment process is repeated with each gene location extended
to flanking regions, consisting of 1000 base pairs both up- and down-stream of the
annotated location. If no gene is found in the extended range, the hit is termed inter-
genic. Finally, in the case of overlapping genes, a probe may align to one location yet
be mapped to more than one gene, in which case the final annotation would depend
on the results of the transcriptome analysis.
Transcriptome analysis repeats the BLAT alignment process using transcript se-
quences as targets for each probe. For the transcriptome, only transcripts with RefSeq
accession numbers beginning with NM or NR (known transcripts) were used (i.e., pre-
dicted models with accessions starting with XM and XR were not included) (Pruitt
et al., 2012). Confidence in the gene assignment of each probe was obtained by map-
ping the transcripts to which the probe aligned back to their respective genes. Only
when the gene ids obtained by genomic and transcriptomic alignment agreed was the
probe assigned a gene id and location label.
3.2.3 Exon mapping
When a probe is determined to map to a unique gene, the latest available exon data
for that gene is downloaded from NCBI (Pruitt et al., 2012). Exons with alternate
splice sites are re-annotated using a method similar to that described by Anders et
al. (Anders et al., 2012), in which the alternate parts of each exon were given a
unique designation of the exon number plus a letter of the alphabet, labeled sequen-
tially. Each probe location is matched to the exon(s), intron(s), or flanking region(s)
it overlaps, and the label created in the format geneid.feature1 feature2. No
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location label is provided for genes for which no exon information is available from
NCBI.
3.2.4 Probe scoring
Scores allow the user to weight the expression value results according to the presumed
reliability of the probe, based on the uniqueness of its alignment to the genome (and
transcriptome), the quality of that alignment (i.e., whether or not there were any
mismatches or gaps in the alignment), and its location (in an exon, intron, or other).
The pipeline allows the user to set values for scoring, e.g. what penalty should be
assessed for having a mismatch or gap in the alignment. Default scoring values for
location and uniqueness scores are shown in Table 3.2. Each probe is also given
a quality score: 100 if there are no gaps or mismatches, 50 if there is one gap or
mismatch, or 0 if there is more than one gap or mismatch. The uniqueness score then
counts for 50% of total score, location and quality scores count 25% each towards
total score.
Combining scores for Affymetrix probe sets
Affymetrix microarrays are designed to produce expression values for probe “sets”,
(usually) eleven probes that map to the same gene, often with overlapping locations.
If all the probes in a given set map to the same gene and location, the individual
probes scores are simply averaged together to produce a probe set score. If all probes
map to the same gene but to different locations within the gene, frequencies for the
probe set are calculated for each location given (e.g., 82% exonic, 18% intronic), and
the best one is used for the location annotation, assuming the best frequency is greater
than 50%. If not all probes in a set, but more than half, map to the same gene, that
gene is used for annotation. In such a case, the total score is reduced by the percent
of probes that do not map to the best gene, e.g., if 9/11 probes map to one gene and
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2/11 to another, the total score would be 0.82 times the average of all probe scores.
3.2.5 Implementation
Once probe scoring is completed, the SCOREM algorithm can be applied to an appro-
priate gene expression data set using the gene annotations assigned in above. Since
the goal of the implementation is to be able to compare multiple data sets from differ-
ent sources, it is necessary to consider the relative thoroughness of each experiment as
well (Ramasamy et al., 2008). Here, each experiment is assigned an experiment score
E based on the number of samples included in each side of the experiment (control
vs. treatment, for example). Given that N1 and N2 are the numbers of samples in
the two conditions being compared and Nmin is the minimum desirable number of
samples (default value is 3), then
E =
(N1+N2)
2
Nmin
. (3.1)
The differential expression values (log2 fold change, or m-values) and FDR-corrected
(Benjamini and Hochberg, 1995) p-values calculated by SCOREM are subsequently
combined with the probe scores from GRASPEM and the experiment score creating
weighted expression values (W) for each gene in each experiment, as follows. Here,
M is the fold-change, P is the p-value, S is the probe or probe set score and E is the
experiment score.
W = M × (1− P )× S × E. (3.2)
3.2.6 Visualization
Using the gene tables from NCBI, I created R functions that draw plots of all known
exons and transcripts of a given gene, along with all probes in the database that map
to that gene. For each of these probes, information on their scores is shown, as is
information on their different expression in any given experiment(s), if any. Discords
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can be automatically flagged in the results and their mappings examined sequentially.
Figure 3·5 shows an example of the output of the GRASPEM visualization tool, which
plots all probes that map to a certain gene against all known transcripts for that gene.
3.3 Results
The main rationale for re-annotation and scoring of probes is to enable valid and
robust cross-platform comparison of microarray data. A necessary prerequisite for
such comparisons is that the platforms are sufficiently equivalent to provide results.
Thus, the platforms were assessed in terms of the range of their probes’ scores, the
distribution of gene locations, and the accuracy of the original manufacturers annota-
tions. Overall, the ability to compare the results of multiple experiments performed
on different platforms was also examined.
3.3.1 Comparison of scores across brands
Figure 3·2 shows the distribution of scores for each brand, while Table 3.3 shows
a summary of the categories of scores (good, failing, and unmappable) by brand.
Agilent appears to have the “best” scores, with the highest mean score (85, compared
to 77-78 for Illumina and Affymetrix) and the lowest number of “failing” (less than
60) scores at only 9%, vs 19% and 15% for Affymetrix and Illumina, respectively.
Illumina also had the lowest number (18%) of unmappable probes (probes that did
not map anywhere in the genome, or mapped to an intergenic region, or mapped to
more than one gene).
3.3.2 Comparison of annotations across brands
Figure 3·3 shows the distribution of the types of locations to which each brand’s
probes map. Agilent has the highest percentage of probes that map to known mRNA
(exons, UTRs, or splice junctions) at 59%, the range was 48-59%. For all brands, the
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number of probes that can cross-hybridize to more than one target is under 5% (range
of 3-4%). Table 3.4 shows a summary the number of probes and genes represented on
each platform as well as the number of probes that map to exons and the number of
exons covered by those probes. It also shows the average number of discords detected
across 114 experiments (detailed in Chapter 4), provided as an estimate of the ability
of each platform to detect alternate splicing.
Figure 3·4 shows that the accuracy of the manufacturer-supplied annotation for a
specific platform varies greatly even within a brand. The number of “correct”annota-
tions for Affymetrix, for instance, ranges from a low of 44% for the mouse mgu74cv2
GeneChipr to 95% for the human hgfocus GeneChipr. The average number of
“correct”annotations over all platforms is only 78%, indicating that a great deal of
published data is likely to be incorrect if only the original annotations are used.
3.3.3 Comparison of expression measurements across platforms
The experimental agreement obtained between platforms was compared using a set
of experiments testing the effect of estrogen administration on the breast cancer cell
line MCF7. Four experiments were chosen based on the similarity of their protocols:
two on Affymetrix GeneChip, one on Illumina and one on Agilent. The SCOREM
tool was run on these data sets, using its built-in function for determining differential
expression based on a sigmoidal function (see Chapter 2). Weighted scores were
generated as described in Methods. From these, I generated a list of which genes were
shown to be differentially expressed and in which direction (up- vs down-regulated),
and compared those results both within the same platform and across platforms. The
cross-platform agreement compared favorably with the within-platform comparison
(Table 3.5 and Figure 3·6).
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3.3.4 Implementation of the visualization tool
Figure 3·5 shows an example of the output of the GRASPEM visualization tool. All
probes that map to a certain gene are plotted against all known transcripts for each
gene, and the direction of differential regulation is shown in the legend. The groupings
of redundant probes or probe sets as determined by the SCOREM pipeline is also
shown.
3.4 Discussion
The goal of GRASPEM was twofold: to align and reannotate microarray probes
with current genome assembly information, and to assign scores to each probe to
reflect their likely reliability. This was done for multiple platforms for three different
brands, plus other custom platforms. Comparison of the scores and locations for
different brands shows that no brand is an obvious better performer than any other.
Therefore, results for individual probes should be considered, regardless of brand, as
an insight into that probe’s likelihood of providing accurate and reliable measures of
expression.
3.4.1 Probe locations and implications for reliability
Figure 3·3 shows the distribution of the types of locations to which each brand’s
probes map. Scores in part reflect these locations, as they are presumed to affect the
reliability of the probes, that is, their ability to report consistent results for a given
gene.
Probes labelled EXUTR (exon or UTR) are considered the most reliable, although
there may be occasions when an (as yet un-annotated) alternate splice site alters the
boundaries of an exon such that the probe is not able to hybridize to that transcript.
Probes labelled SJ (splice junction) should also be considered reliable, since they
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do map reliably to known transcripts, if not the genome. (Some probes that map to
splice junctions have genomic hits with a gap, but others are not able to be aligned
by BLAT. Only the latter are included here.) Reliability may be slightly lower than
EXUTR probes, since any alternate splicing around the exons in question are cer-
tain to prevent hybridization. These probes may be considered reliable for certain
transcripts only.
The label OVRLP refers to a probe that aligns to exonic or UTR regions of one
gene while at the same time aligning to an intron of another gene that overlaps the
first gene on the genome. Since it is possible that under some circumstances the probe
might be hybridizing to a novel isoform of the second gene, the ability of these probes
to produce a reliable signal is assumed to be lower than that of either EXUTR or
SJ probes. It is to be noted that this specifically does not refer to probes that map
to exonic regions of both genes. Such probes are labeled cross-hybridzers (XHYB)
instead, along with any probes that have a equal likelihood (based on the quality of
the alignments) of hybridizing to more than one gene from different locations.
Probes labelled INTRON do not align with any known transcript, but do align to
an intronic region of a known gene. This could indicate the existence of an alternate
splice site/version of the closest exon, and an additional alternate transcript of the
gene. If this is not the case, the presence of such a sequence in the total RNA of
a sample could indicate a retained intron in a non-coding transcript, or even the
presence of a microRNA within the gene.
Probes labelled FLANK do not overlap with the longest (as defined by the most
extreme known transcription start and end sites) annotated version of any gene, but
do align somewhere within the flanking regions (+/- 1000 base pairs) of a known gene.
Such regions may in fact be part of a longer version of the gene, particularly as part
of extended UTRs, i.e., they may be part of alternate promoter regions (upstream)
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or polyadenylation sites (downstream) of the nearest gene.
Similarly, probes labelled IG (intergenic) do not overlap with any known gene
or its flanking region (+/- 1000 base pairs), but such probes may also be part of
alternate UTRs, that extend more than 1000 base pairs from the closest gene. The
pipeline can be run with the flanking region definition set to a larger (or smaller)
value, to extend the search for nearest genes. If the distance to the nearest gene is
much greater, the probe may be hybridizing to an as yet unannotated RNA, either
mRNA or non-coding RNA such as a microRNA, lncRNA, or enhancer RNA. At the
time of this writing, the pipeline does not measure distance to the nearest gene for the
intergenic probes, but this information could be ascertained on an individual basis
if needed, e.g. if a particular intergenic probe shows marked differential expression
under some condition of interest.
Probes that do not align anywhere in the known genome or transcriptome are
labeled NONE. As genome and transcriptome updates are released, some of these
annotations may change.
3.4.2 Exon mapping and visualization
The visualization tool is provided to allow the user to examine the data for any given
gene, both expression and location, in greater detail. The tool, accessed through R,
takes a set of differential expression data and a gene id and create a map of all the
probes (in all platforms previously processed by GRASPEM in that environment),
against all the known transcripts of that gene. The direction of differential expression
for each probe is indicated in the legend. This allows the user to visually inspect the
probe locations, to attempt to correlate any discordance in regulation (i.e., some
probes up and some down) with their transcript and exon locations. As discussed in
Chapter 2, this type of post hoc analysis may lead to deeper insights into the nature
of expression regulation, or even implicate the existence of additional, novel isoforms.
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3.5 Conclusions
Various groups have proposed methods to deal with the problem of probe annotations.
Most of these (Dai, 2005; Ferrari et al., 2007; Harbig et al., 2005; Barbosa-Morais
et al., 2010; Lu et al., 2007) were performed only on one type of platform, and
ignored (or removed entirely (Ferrari et al., 2007)) redundant probe sets, a limitation
discussed in detail in Chapter 2. Kim et al. (Kim et al., 2011) performed a cross-
platform re-annotation, but made no attempt, beyond removing unmappable probes,
to assign a score or other measure of quality to the resulting annotations. Barbosa-
Morais et al. (Barbosa-Morais et al., 2010) thoroughly assessed the quality of each
probe, but did so only for Illumina BeadArraysr. While other toolkits have been
developed that also offer transcript-based visualization of probe mapping (Lu et al.,
2007), so far no one has done this in a platform-independent manner. In this work I
combine the best aspects of these other approaches to create a pipeline that outputs
expression values that are more reliable and robust than existing methods.
As a consequence of developing this method, my analysis shows that no one plat-
form is inherently better than any of the others, so there is no reason to exclude any
data set out of hand. There is also no reason to exclude data entirely if it comes
from a probe that does not map to any known transcript. New transcripts are being
added to databases on a daily basis, and so data that not interpretable today may
very well provide significant information at a later date. Running (and rerunning)
the GRASPEM pipeline on additional platforms can easily ensure that the analysis
of gene expression being undertaken is both as accurate and reliable as the current
genome assemblies allow.
By identifying discords (probes that represent the same gene but are indicating
different directions for differential expression) and using the visualization tool to
examine the locations of these discordant probes, an understanding of transcript-
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specific regulation and/or identification of novel splice variants or splice sites may
be achieved. Such instances may become important in understanding the specific
biological process under investigation.
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Table 3.1: Distribution of types of expression data available in NCBI’s
GEO (data retrieved June 14, 2013).
Type of Expression Data Percent of Total
Oligonucleotides (in situ, spotted, or bead-based) 94
High-throughput sequencing 5
Other (SAGE, RT-PCR, MPSS) 1
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Table 3.2: Summary of probe scoring algorithm. (a) The labels used
to describe the locations to which probes map, used throughout this
chapter. (b) “Hits” refers to the number of alignments between a probe
and the genome (G) and the transcriptome (T). The transcriptome hits
number refers to the number of genes to which the transcript hits map.
(c) A description of the probes included in that category. (d) Scores
are the scores given for uniqueness and location.
(a) (b) Hits (d) Scores
Label G T (c) Description Uniq* Loc
EXUTR 1 1 Perfect probes that align to the genome in
one site, overlapping with one gene and with
all transcriptomic alignments to the same
gene, are part of either exons or UTRs.
100 100
SJ 0 1 Probes that have a hit to the transcript(s)
of a single gene but do not align to the
genome may map to a splice junction.
90 100
INTRON 1 0 Probes with no transcriptomic hits but a
single, unique genomic hit, overlapping with
one gene but not to its exons or UTRs, align
to an intron.
70 100
FLANK 1 0 Probes with no transcriptomic hits but a
single genomic hit in the flanking regions
(within 1000 base pairs up- or down-stream)
of a known gene.
70 100
IG 1 0 Probes with no hits to the transcriptome
and a unique hit on the genome in an
intergenic region (not within 1000 base pairs
of any known gene).
30 100
OVRLP 1 >1 Probes that map perfectly to the
transcript(s) of one gene but also to an
intron or flanking region of another gene at
the same location.
100 75
XHYB >1 >1 Probes that map perfectly to the
transcript(s) of more than one gene.
100 -50
each
NONE 0 0 Probes that do not map anywhere in the
annotated genome or transcriptome.
0 0
*If any of these also have additional intergenic hits, 10% is subtracted from the uniqueness
score for each.
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Table 3.3: Summary of probe scores by brand showing (a) the mean
scores for all probes, (b) the percent of probes with a score of less than
60, (c) the percent of probes given a score of zero, and (d) the percent
of probes that could not be reliably mapped to a single gene (location
was NONE, IG, or XHYB).
(a) (b) (c) (d)
Brand
Average
Score
% Failing
Scores
% Zero
Scores
% Un-annotated
Probes
Affymetrix 77.6 19.2 12.6 26
Agilent 84.7 8.9 18.4 19
Illumina 77.4 14.5 36.8 18
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Table 3.4: Profile of probe mapping by platform. Total Probes is
the number of probes or probe sets (for Affymetrix) on the microarray.
Total Genes is the number of genes represented by those probes/probe
sets. Mapped Probes is the number of probes/probe sets that were
mappable, including those mapping to exons, UTRs, introns, flanking
regions, and multiple exons across splice junctions. Exonic Probes is the
number of probes/probe sets mapping to exons and UTRs, including
those mapping to multiple exons across splice junctions. Average Exons
is the average number of exons covered by the Exonic Probes. Average
Discords is the number of discordant probe sets detected across 114
experiments.*
Total Total Mapped Exonic Average Average
Platform Probes Genes Probes Probes Exons Discords*
Affymetrix
hgfocus 8793 8048 7916 7509 1.7 <0.01
hgu133a 22283 12523 18761 16443 1.7 0.02
hgu133a2 22277 12523 18761 16443 1.7 0.02
hgu133plus2 54675 19671 40385 28604 1.6 0.48
hgu95a 12626 8602 10625 9707 1.6 <0.01
hgu95av2 12625 8600 10624 9707 1.5 0.01
mgu74av2 12488 8136 8937 8459 1.6 <0.01
mgu74bv2 12477 6939 8643 7470 1.4 <0.01
mgu74cv2 11934 4010 4835 3094 1.2 <0.01
moe430a 22690 12822 18988 17767 1.7 <0.01
mouse4302 45101 18416 34522 26254 1.6 0.03
rat2302 31099 14105 20549 11000 1.7 <0.01
rgu34a 8799 4729 6372 4455 1.9 <0.01
Agilent
mouseG4121A 20872 16600 17348 15455 1 0.03
mouseG4122F 41264 20174 34149 26166 1 0.72
humanG4122F 41094 20678 31235 24773 1 0.47
Illumina
human6v2.0 48702 20630 27509 21611 1 <0.01
humanRef8v3.0 24526 17782 23441 22014 1 <0.01
humanWG6v3.0 48803 20793 31614 26214 1 0.18
humanHT12v3.0 49576 20793 31614 26214 1 <0.01
* This data is based on data included in Chapter 4, and is provided as an estimate of the ability of
each platform to detect alternate splicing.
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Table 3.5: Intra- and inter-brand overlap of gene expression results.
P-values were obtained from the chi-squared value for the size of the
observed overlap compared to the expected overlap between the two
sets.
Brands of Compared
Data Sets*
# of
Genes
Observed
Overlap
Expected
Overlap
χ2 p-value
Affymetrix1, Affymetrix2 1272, 551 299 35 < 10−300
Affymetrix1, Illumina 1272, 734 459 47 < 10−300
Affymetrix2, Illumina 551, 734 230 20 < 10−300
Affymetrix1, Agilent 1272, 1463 959 94 < 10−300
Affymetrix2, Agilent 551, 1463 452 41 < 10−300
Illumina, Agilent 734, 1463 599 54 < 10−300
*Data Sets: Affymetrix1 = GSE11324; Affymetrix 2 = GSE11352; Illumina = GSE22213;
Agilent = GSE24065
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(GSE files)
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Obtain probe sequences 
from GEO (GPL file)
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Convert transcript
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Figure 3·1: The Global Re-Annotation and Scoring Pipeline for Ex-
pression Microarrays (GRASPEM) workflow.
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Figure 3·2: Distribution of probe scores by brand. The red line indi-
cates the level of “passing” scores (60). Boxes indicate the interquartile
ranges (IQR, 25th to 75th percentiles). The dark line inside each box is
the median score. Circles indicate outliers (scores more than 1.5 times
the IQR from the median, indicated by the horizontal lines).
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Figure 3·3: Summary of probe locations by brand. EXUTR = maps to
an exon or untranslated region (part of mRNA); SJ = maps to a splice
junction; INTRON = maps to an intron of a known gene; FLANK
= maps within 1000 base pairs up- or down-stream of a known gene;
OVRLP = maps to two overlapping genes; XHYB = cross-hybridizer
(maps to more than one gene); IG = maps to an intergenic region (not
within 1000 base pairs of a known gene).
63
0 20 40 60 80 100
UnmappableDifferentSame
humanHT12v3.0
humanWG6v3.0
humanRef8v3.0
human6v2.0
humanG4112F
mouseG4122F
mouseG4121A
rat2302
rgu34a
mgu74cv2
mgu74bv2
mgu74av2
mouse4302
moe430a
hgu133plus2
hgu133a2
hgu133a
hgu95av2
hgu95a
hgfocus
A
ffy
m
et
rix
A
gi
le
nt
Ill
um
in
a
Percent of Probes
Figure 3·4: Comparison of GRASPEM annotations to original an-
notations, by platform. “Un-annotated” refers to probes that could
not be mapped to a single gene by GRASPEM (includes probes in the
XHYB, IG, and NONE categories).
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Figure 3·5: The GRASPEM visualization tool. All probes that map
to a certain gene are plotted against all known transcripts for each
gene, and the direction of differential expression in a given experiment
is shown in the legend.
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Figure 3·6: The degree of overlap between the lists of differentially
expressed genes between brands (inter-brand overlap) and within the
same brand (intra-brand overlap). See also Table 3.5.
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Chapter 4
Meta-analysis of gene expression regulated
by estrogen across multiple cell types
4.1 Introduction
Estrogen is a steroid hormone that binds to estrogen receptors (ERs), transcription
factors that bind DNA to activate or inhibit transcription of target genes. ERs may
bind DNA directly, at sites called estrogen-responsive elements (EREs), or indirectly,
through other transcription factors. As estrogen is known to both positively and
negatively affect cell proliferation and drive apoptosis (see Table 1.1), the genes reg-
ulated by estrogen include many genes involved in these processes. Understanding
which genes are regulated by estrogen in which cell types may reveal overlapping or
entirely separate regulatory pathways for these actions.
Cross-tissue meta-analysis was undertaken to elucidate functional modules and
networks of estrogen-responsive genes. To accomplish this, the following questions
were raised and addressed: are the same genes within each pathway being regulated
in all cell types, and are they regulated in the same directions? Which pathways are
activated/inhibited in each cell type? Are the same genes being regulated in com-
mon pathways? Are there any genes showing discordant behaviors (different probes
showing different responses), and do these correspond to different splice variants? If
so, are there any splice variants that are cell-specific?
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4.2 Materials and Methods
4.2.1 Data sources and processing
A total of 54 data sets representing 110 separate experiments were obtained from
GEO Barrett et al. (2013). An additional 2 data sets representing 6 experiments were
obtained from collaborators. Several additional data sets from GEO were excluded
when preliminary processing revealed that there were no genes differentially regulated
at a statistically significant level. The tissue and cell types represented by these
experiments are shown in Table 4.1. Full details are in Table A.1. All data was
processed according to the methods described in chapters 2 and 3: the SCOREM
algorithm was run using the annotations provided by GRASPEM, and the resulting
fold change and p-values were combined with the scores from GRASPEM to create
weighted scores, as shown in Equation 3.2.
4.2.2 Meta-analysis workflow
Various approaches to meta-analysis were implemented and the results compared. A
summary of the steps taken is shown in Figure 4·1; details are given below.
1. Mapping orthologs
Ortholog tables were downloaded from the Mouse Genome Database (Bult et al.,
2013). All mouse and rat Entrez Gene ids were converted to their orthologous human
equivalents and all further analysis was performed using the human ids. Mouse and
rat genes that do not have human orthologs, as well as data from probes that had no
gene annotation by GRASPEM, were excluded from the results.
2a. Pooling by cell type
The initial analysis undertaken was to use simple vote counting (Ramasamy et al.,
2008; Rhodes et al., 2004), to examine the overlap of lists genes differentially expressed
68
in each cell type (disregarding time points). Results from all experiments for a given
cell type were pooled.
2b. Creating gene signatures
Rather than pooling all experiments for a specific cell type, a “gene signature” for
each cell/time point was created by selecting those genes that were statistically over-
represented in the list of all genes differentially expressed for all experiments for
that cell at that time point. Statistical over-representation was calculated for all
cell/time sets for which there was more than one experiment. Statistical significance
was calculated using Fisher’s Exact test, as the numbers of experiments was generally
small (i.e, under 10) (Fisher, 1922). Let kg be the number of times a given gene g
is reported as differentially regulated in this set of experiments, and n be the total
number of genes reported as differentially regulated in all experiments. Given that
N is the size of the universe of genes and K is the number of experiments in the set,
N −Kg is the number of genes other than g determined to be differentially regulated.
The probability that gene g will be chosen k times is given by
P (X = k) =
(
K
k
)(
N−K
n−k
)(
N
n
) . (4.1)
P-values are thus calculated for each gene, and genes with a p-value less than 0.01
are selected into the gene signature. As with the simple vote counting process, the
results are further subject to enrichment analysis for KEGG (Kanehisa et al., 2012)
pathways (see step 5).
3. Combining into groups (vote counting)
Cells were grouped into like categories, e.g., all estrogen-receptor positive (ER+)
breast cancer cell lines (Table 4.1). The common set of genes (those differentially
expressed in all or all but one of the cell types in a group) were then selected for
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further analysis. Resulting groups are shown in Table 4.2.
4a. Selecting “top” genes
For both cell types and groups, the most common (“top”) genes were selected. For
cell types, genes differentially expressed in one third or more of the all cell types
were selected (7 or more out of 19). For groups, genes differentially expressed in
at least 2 (out of 8) groups were selected. A comparison was done to see if the
overlap between lists for each pair of cell types (or groups) represented a statistically
significant overlap, or not, as follows.
Given U as the size of the gene universe, the statistical significance in the overlap
between the lists of differentially expressed genes for two cell types, A and B, can
be determined from J , the Jaccard similarity coefficient or Jaccard index (Real and
Vargas, 1996), given by
J =
|A ∩B|
|A ∪B| . (4.2)
A p-value for J can be obtained from the χ2 value of the expected value of J
compared to the observed value of J , where
E(J) =
E(|A ∩B|)
|A ∪B| =
|A|×|B|
|U |
|A ∪B| . (4.3)
This analysis was repeated for cell groups, where cells were grouped into like cate-
gories, e.g., all ER positive breast cancer cell lines. The common set of genes (those
differentially expressed in all or all but one of the cell types in a category) were then
selected for further analysis; each list was then checked for over-represented KEGG
pathways. Enrichment was determined by Fisher’s Exact test, with p<0.01. This
was done for both the cell-centered lists, and the cell group lists.
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4b. Selecting cell-specific genes
For each cell type, the genes that appeared in more than one experiment, but never
in any experiment in any other cell type, were also selected for further analysis.
5. KEGG analysis
Functional enrichment of each cell type, group, and signature, as well as the top genes
lists for all cells and all groups, was calculated for all KEGG pathways.
6. Select “top” pathways for cell types and groups and signatures
For the KEGG analyses that were done on each cell type, group, or signature, the top
ten pathways (those that were enriched in the most types/groups/signatures, gener-
ally in more than one third of the selections) were compared. For the most common
pathways, the genes regulated in each list, including the direction of regulation (up
or down) were mapped onto the KEGG pathway diagrams.
4.2.3 Weighted Gene Co-expression Network Analysis (WGCNA)
Weighted Gene Co-expression Network Analysis (WGCNA) is a method for detecting
correlation patterns among genes across experiments. It can be used for finding
clusters (modules) of highly correlated genes, for finding hub genes inside modules,
and for correlating modules to external traits (Zhang and Horvath, 2005). This
analysis was carried out with the gene signatures, not the complete set of data, so as
not to bias the results towards most common cell types (there was one column in the
final matrix for each cell/time, instead of multiple columns for MCF7 cells treated for
24 hours, for instance). The average weighted score for each gene in each signature
was calculated, and all the results combined into one matrix. This matrix was then
entered into the WGCNA pipeline (Langfelder and Horvath, 2008).
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First, the signatures were clustered and outliers removed (Figure 4·2). The genes
were clustered to create modules (Figure 4·3), and these were then correlated with
both cell type and time (Figure 4·4). A multidimensional scaling plot was done to
examine the similarity between/within the modules (Figure 4·5). Enrichment analysis
for KEGG pathways was also performed on modules of interest.
4.3 Results
4.3.1 Comparison of “top” gene lists
“Top” gene lists were created by selecting the genes expressed most often across
multiple cell types, or groups of cell types (Table 4.2). The goal of creating these lists
was to see how many genes were regulated in more than one cell type (and how many
were cell-specific), and if those genes are regulated in the same or different directions
in different cell types.
First I examined the significance of the overlaps between different “top” gene
lists for each cell type. The Jaccard Similarity Coefficient was used as the metric of
similarity between the cell types. The most highly similar pairs of cell types are shown
in Table 4.3; a complete list is in Table A.2. It is interesting to note that not all of
the most similar cell types belong to the same groups. In particular, the MCF7 and
T47D estrogen-receptor positive breast cancer cell lines are more similar to the ovarian
cancer cell line EOC and to whole uterus than they are to another estrogen-receptor
positive breast cancer cell line, BT474, or to estrogen-receptor negative breast cancer
cell lines or whole mammary tissue.
4.3.2 Cell-specific gene regulation
In addition to the analysis of the common genes, I also examined the lists of cell-
specific differentially expressed genes. As shown in Figure 4·6, the majority (two-
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thirds) of all genes differentially regulated in response to estrogen are regulated in
more than one cell type. Figure 4·7 shows that these unique genes are spread fairly
evenly across cell types, with the the vast majority of genes (on average, 93%) regu-
lated in any given cell type also regulated in at least one other cell type. When cell
types are combined into groups, there is a greater proportion of unique genes. Fig-
ure 4·8(a) shows the intersection between the four largest sets of genes regulated by
estrogen, for each cell group. Figure 4·8(b) shows the proportions of unique, shared,
and common (to all four sets) genes in each group.
Each set of unique genes (by cell type and by group) were tested for functional
enrichment. Of the cell type sets, the only set that had a significant result was that
of the whole uterus, in which the KEGG olfactory transduction pathway was very
significantly enriched (p < 1.35 × 10−60). This list included 48 genes in that path-
ways, of which 42 were olfactory receptors. There were an additional 20 olfactory
receptor genes that were also expressed in MCF7 and/or thymus (i.e., not unique
to uterus), although enrichment of this pathway did not achieve statistical signifi-
cance in those cell types. While there is no known function of olfactory receptors
in uterus, expression of these genes in tissues other than olfactory epithelium has
been documented (Feldmesser et al., 2006), and a role in sperm chemotaxis has been
established (Fukuda et al., 2004). Of the cell group sets, olfactory transduction was
enriched again for uterus. The immune-related cell group showed enrichment in cell
signaling and immune-related pathways, including the cytokine-cytokine receptor in-
teraction, cell adhesion molecules (CAMs) and chemokine signaling pathways, among
others. The unique sets for estrogen-receptor-positive breast cancer and ovarian can-
cers interestingly had no enriched pathways at all, perhaps indicating a greater degree
of spurious gene expression in these cells: over a third of the probes that were in this
category were unannotated, either mapping to intergenic regions or nowhere in the
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current genome assembly. The most common genes (788 genes, seen in the center of
Figure 4·8(a)), were also tested for functional enrichment. Results are shown in Table
4.4.
4.3.3 Gene signatures and WGCNA
By creating gene signatures for cell and time, changes in the regulation of various
genes over time can be examined. By using gene signatures, each cell type/time point
is given equal weight in subsequent analysis. Otherwise, cells with more experimental
data than others (for instance, MCF7) dominate the results from the analysis. Details
on the gene signatures are in Table A.3.
Weighted Gene Co-expression Network Analysis (WGCNA) is a method for de-
tecting correlation patterns among genes across experiments. It can be used for
finding clusters (modules) of highly correlated genes, for finding hub genes inside
modules, and for correlating modules to external traits (Zhang and Horvath, 2005).
The WGCNA R package was utilized to cluster the signatures, find functional mod-
ules, and assess the correlation of the modules with time and cell type (Langfelder
and Horvath, 2008).
First the program clusters the samples, to look for outliers. As a result, the EOC
data was removed (Figure 4·2). Genes were then clustered into modules based on
behavior across signatures (Figure 4·3). Lists of genes from modules in which gene
behavior was highly correlated with cell type (purple and green, see Figure 4·4), as
well as from modules that showed strong intra-modular similarity (blue, black and
turquoise, see Figure 4·5), were analyzed for functional enrichment as well. In general,
the same pathways reported as enrichment in the “top” gene lists were enriched here,
as well (top 10 pathways for each module shown in Table A.4, common pathways are
in italics).
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4.3.4 KEGG pathway enrichment
The KEGG Pathways database details molecular interaction and reaction networks
for cellular processes and information processing Kanehisa et al. (2012). The goals of
the enrichment analysis were to see which pathways were enriched in each cell type (or
group, or signature), and if the same pathways were enriched in multiple cell types.
The goals also included evaluating if the same genes are differentially expressed across
cell types in a given pathway, and, if so, if they are differentially expressed in the same
or different directions. Overall, the same pathways were enriched no matter which
gene lists were used. The top most common pathways enriched in the gene lists are
shown in Table 4.5. (For a complete list, see Table A.5.) The pathways marked with
an asterisk are those that were shown to be enriched no matter the method used (they
were enriched in all four types of analyses as shown in Figure 4·1). Since the overall
goal of the meta-analysis was to understand how estrogen both inhibits and activates
cell proliferation in different cell types, of the most interest here are the cell cycle and
p53 and MAPK signaling pathways, as well as the associated apoptosis and TGF-β
pathways, all of which are involved in cell proliferation and apoptosis. The canonical
MAPK ERK pathway drives proliferation, while the JNK/p38 portion of the MAPK
signaling pathways inhibits proliferation and may drive apoptosis. Figure 4·9 shows
a simplified schematic of these KEGG pathways, and the key genes involved in each.
The role of some key genes is described in Table 4.6.
4.3.5 Proliferation Control Pathways
The differential expression in response to estrogen of genes involved in the above
pathways are shown in two heatmaps. Also included are genes in the Lifeguard
family that are known to be inhibitors of apoptosis (Hu et al., 2009). Figure 4·10
shows differential expression in genes that drive proliferation, while Figure 4·11 shows
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differential expression in genes that inhibit proliferation and/or drive apoptosis. This
heatmap also includes genes that have mixed effects. (Both heat maps include all
data available, not in any top gene list or signature.) In the proliferation-activating
genes, the estrogen-receptor positive breast cancer cell lines MCF7 and T47D show the
strongest changes over these pathways, with many genes up-regulated over time. At
the earliest time points (A, one-half to two hours), MCF7 proliferative genes showing
any response are largely down-regulated, including cyclin D2 (strongly) and D3; only
a few are up-regulated, including c-myc. Myc is in fact upregulated at all time points
in all three ER positive breast cancer cell lines, as well as whole thymus and ovarian
cancer (EOC). c-fos is up-regulated in MCF7 and T47D as well as whole uterus
and whole thymus. In MCF7, at later time points, more and more up-regulation
of proliferative genes is seen, especially of cyclin D1 and D3, and CDK4 (although
CDK6 is down-regulated), E2F1/2, cyclin E2 and CDK2, the MCMs and ORCs and
associated CDCs 6 and 45, and cyclin A. Cyclin B and CDK1 show a distinct increase
in up-regulation over time. The pattern of estrogen-mediated differential expression
in the T47D cell line largely resembles that in MCF7 cells. They do however up-
regulate different APC/C genes; MCF7 up-regulates ANAPCs 1 and 7 while T47D
up-regulates 2 and 5. In the BT474 cell line, only c-myc shows a strong response to
estrogen, being up-regulated at all time points. In whole mammary tissue, estrogen
seemed to cause a response only in levels of EGFR, which was up-regulated. Whole
uterus at time point D (24 hours) had the strongest result, looking very similar to
MCF7 at the later time points. Endometrial cancer cells did not show much response
to estrogen, the ovarian cancer EOC did, also similar to MCF7 and whole uterus. As
expected, the ER-negative breast cancer cell lines MDAMB231 and SKBR3 showed
almost no response to estrogen in proliferative genes. Notably, neither did the vascular
smooth muscle cells, which are inhibited from proliferation by estrogen. The bone
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marrow cells also showed little to no response, but whole thymus unexpectedly showed
a consistent up-regulation of most of the proliferation-related genes.
Likewise, many anti-proliferative and pro-apoptotic genes, including p130, p300,
and the CDK inhibitors, are down-regulated in MCF7 cells and uterus. Some down-
regulation is seen in Ishikawa (endometrial) and EOC (ovarian) cancer cells as well.
Strangely, most of these genes are also up-regulated in thymus as well as in T47D cells,
in opposition to the up-regulation of the pro-cell division genes discussed above. There
is some inhibition of proliferation due to up-regulation of genes in the TGF-β pathway
in vascular smooth muscle cells, but no large up-regulation of anti-proliferative genes
is seen in these cells.
4.4 Discussion
A meta-analysis of gene expression utilizing data from different cell types from dif-
ferent species, prepared in different laboratories with different technologies and pro-
cessing methodologies, might seem an impossible task. One obvious complication is
a lack of orthology information when doing cross-species comparison. Complications
in gene expression in general were discussed in Chapters 2 and 3, including alter-
native splicing, inclusion of partially processed or unprocessed mRNA in samples,
and probe reliability. Additional complications affecting gene expression analysis in-
clude the genome integrity (or lack thereof) in cancer cell lines, and the presence of
more than one cell type in whole tissue preparations. For cancer cell lines (as well
as primary tumor samples), issues with genome integrity include the possibilities of
gene amplifications, translocations, and the loss of chromatin organization. Another
complication is the comparison of single cell culture samples to whole tissue samples,
which contain more than one cell type, possibly with opposite changes in gene expres-
sion. Despite these complications, overall the similarity of results across these diverse
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conditions shows that obtaining meaningful results from such an analysis is not only
possible, but more credible than any single set alone.
4.4.1 Estrogen-regulated genes
This analysis shows that there is significant overlap of which genes’ expression is
regulated by estrogen in different cell types, even if the direction of regulation is not
the same (Table 4.3). From a gene-centric point of view, 67% of all genes regulated
by estrogen are shared, while 33% are unique to some cell type (Figure 4·6). From
a cell-centric perspective, each cell type has a very small fraction of genes that are
unique to that cell, with the average at 5% (Figure 4·7). After grouping cell types
together, the unique fraction is even smaller (3%). Since genes that are regulated so
infrequently may be the result of a noise signal, the analysis focused on genes that
were repeatedly shown to be differentially expressed in several cell types. Looking at
the patterns of expression among these common genes gives insight into how estrogen
interacts with different signaling pathways in cells.
4.4.2 Pathways
The goal was to determine if the same pathways are overrepresented in more than one
cell type, and if the same genes within each pathway are being regulated in those cell
types. As shown in the results, the former is certainly true. Three of these pathways
were selected for further inspection: cell cycle, p53 signaling, and MAPK signaling.
The related pathways TGF-β signaling and apoptosis are also included (Figure 4·9).
A caveat to this analysis is that it is limited to genes with KEGG annotations; many
genes differentially expressed in response to estrogen have no functional annotations
and so are excluded from functional enrichment analysis.
In cell types which are known to proliferate in response to estrogen, we expect to
see up-regulation of genes that promote proliferation and down-regulation of genes
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that inhibit proliferation or induce apoptosis. These cell types include in breast cancer
cells lines that are estrogen-receptor (ER) positive as well as in uterine and ovarian
cells. We expected to see no significant regulation of these genes in ER-negative
breast cancer, and the opposite patterns in vascular smooth muscle cells, as estrogen
is known to inhibit proliferation and/or induce apoptosis in these cells (Karas et al.,
2001; Yang et al., 2007). The transcriptional effects of estrogen in adipose, liver,
thymus, and bone marrow were not expected to involve proliferation, either.
As shown in Figure 4·10, the response of genes in the proliferation-related path-
ways was partly as expected. MCF7 and T47D breast cancer cell lines showed a
marked increase in genes driving proliferation, as did whole uterus (at least through
time point D, 24 hours) and EOC ovarian cancer. BT474 showed only an increase in
c-myc. The vascular smooth muscle cells showed no up-regulation of these genes (as
expected), and, interestingly, no down-regulation either. The ER-negative cell lines
showed no response either way in response to estrogen, indicating that the results seen
in the other cell types must be due at least in part to estrogen interacting with an
estrogen receptor, and not solely to ER-independent pathways. Several of the genes
regulated (FOS, HRAS, and BCL2) are known to be direct (ERE binding) targets of
estrogen receptor alpha or indirect targets, binding via Sp1 (E2F1) or AP-1 (cyclin
D1, MYC) (Jin et al., 2005).
Figure 4·11 shows the opposite side of these pathways, the genes inhibiting pro-
liferation or inducing apoptosis. Here, again as expected, MCF7 and whole uterus
cells showed a distinct down-regulation of many of these genes. Uterus shows down-
regulation of p53 at two time points; p53 has been shown to be an ERE-independent
target of ERα via NFκB (Jin et al., 2005). T47D cells, however, showed some up-
regulation of these genes, and BT474 continued to show no response. (The MCF7 cell
line does not have known p53 mutations, while BT474 and T-47D are both known to
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have p53 mutations, as does MDAMB231; SKBR3, EOC, and Ishikawa also contain
wild-type p53 (Forbes et al., 2011).) Aortic smooth muscle cells show up-regulation
of a few genes, but mesenteric artery cells shown down-regulation. The general lack
of differential expression in these categories is noteworthy, though, as estrogen is
known to inhibit proliferation in these cells. How it does so does not seem to directly
involve these pathways, however. One possible pathway for regulation is metabolic
pathways, specifically oxidative phosphorylation in mitochondria, previously shown
to be regulated by estrogen in vascular tissue (O’Lone et al., 2007; Mattingly et al.,
2008).
It is also worth pointing out that the vascular samples are actually tissues, not
purified cell types, and so the results may be skewed by the amount of cells other
than smooth muscle, namely epithelial, are in the sample. This is true for other whole
tissues as well. Uterus, for instance, contains both myometrium and endometrium,
which may show different responses to estrogen that cannot be ascertained from the
mixture. In the WGCNA sample clustering, whole mammary was clustered with
inguinal fat, presumably because whole mammary tissues contains a great deal of
adipose tissue. Inguinal fat also contains lymph nodes, which may explain any simi-
larity to thymus data.
Whole thymus showed the most surprising results. While estrogen is known to
cause a decrease in thymic size (Selvaraj et al., 2005; Cooke et al., 2006), the mech-
anisms by which is does so are not known. These results show that exposure to
estrogen leads to up-regulation of both proliferation-activating and -inhibiting genes.
Bone marrow cells, on the other hand, show no such up-regulation. As whole thymus
is a tissue, containing multiple cell types, as noted above the responses of any one
particular cell types within the tissue cannot be separated from the aggregate.
One gene stands out as being regulated the most often by estrogen: thrombospondin-
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1 (THBS1, EntrezGene id 7057). THBS1 was the one gene common to seven out of
eight groups (eleven out of nineteen cell types) of genes regulated by estrogen. It is
a member of the TGFβ signaling, p53 signaling, PI3K-Akt signaling, ECM-receptor
interaction and focal adhesion pathways. It has been shown to be a direct target
of estrogen receptor alpha, and to play a pro-growth role in breast cancer cell lines
(Hyder et al., 2009). It is consistently up-regulated in almost all cells/time points
(Figure 4·11, in the set of ”mixed effects” genes). Clearly it plays a role in many
other cell types besides breast cancer, and so may be a key factor in the estrogen
transcriptional regulatory network.
4.5 Conclusions
The meta-analysis of estrogen-regulated gene expression showed significant overlap in
genes regulated across diverse cell types, as well as the functional pathways enriched in
those genes. Most notably, the pathways involved in cell proliferation were markedly
enriched in several of these cell types. In breast cancer cells positive for estrogen
receptors, as well as uterine tissue, genes that promote cell proliferation were up-
regulated, and genes that inhibit proliferation were notably down regulated. In breast
cancer cells negative for estrogen receptors, no such regulation was seen. In vascular
smooth muscle cells, neither set of genes showed much change. This shows that
estrogenic control of cell proliferation depends upon the presence of estrogen receptors
and likely involves different mechanisms in cells in which estrogen drives proliferation
vs. those in which estrogen inhibits proliferation.
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Table 4.2: Combination of lists of “top” genes in each cell type into
groups, and the sizes of the resulting lists.
Top Gene Top Gene
Cell Type Count (Cell) Cell Group Count (Group)
GonFat 262
Adipose 372IngFat 127
MCF7 12733
ER+ breast cancer 2433BT474 190
T47D 2810
MDAMB231 34
ER- breast cancer 72SKBR3 40
cd44 119
Immune 113ckit 70
wh.thym 8257
wh.liver 174 Liver 174
EOC 2635 Ovary 2635
wh.ut 10598
Uterus 95
Ishik 135
myomet 37
HeLa 15
ASMC 180
Vascular 243MASMC 71
ER = estrogen receptor
83
Table 4.3: Statistical significance of gene list overlap between pairs
of cell types where the Jaccard Index is greater than 0.1. |A| and |B|
indicate the size of the two lists. |A ∩ B|obs is the observed size of the
intersection. |A∩B|exp is the expected size of the intersection (Equation
4.3). J is the Jaccard Index (Equation 4.2) and p(χ2) is the p-value for
the χ2 test on the observed and expected values.
Cell Types |A| |B| |A∩B|obs |A∩B|exp J p(χ2)
cd44-ckit 119 70 53 0 0.39 < 10−300
MCF7-T47D 4323 2786 1210 486 0.21 < 10−300
wh.ut-MCF7 4920 4323 1726 858 0.23 2×10−290
MCF7-EOC 4323 2349 939 410 0.16 2×10−199
wh.ut-T47D 4920 2786 1086 553 0.16 6×10−154
wh.ut-EOC 4920 2349 841 466 0.13 5× 10−87
T47D-EOC 2786 2349 501 264 0.11 4× 10−59
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Table 4.4: Top KEGG pathways enriched in the list of 788 genes
regulated by estrogen in common to the four largest cell groups. Exp
# = number of genes from this pathway expected to be a list of this
size. Obs # = number of genes from this pathway observed in this list.
Rank KEGG Pathway Exp # Obs # P-value
1 05200 Pathways in cancer 10.4 32 1.4e-08
2 04512 ECM-receptor interaction 2.7 15 5.8e-08
3 03013 RNA transport 4.8 19 2.8e-07
4 01100 Metabolic pathways 35.7 62 8.8e-06
5 04810 Regulation of actin cytoskeleton 6.7 20 1.1e-05
6 05220 Chronic myeloid leukemia 2.3 11 1.5e-05
7 04141 Protein processing in endoplasmic reticulum 5.2 17 1.6e-05
8 05210 Colorectal cancer 2 10 2e-05
9 03008 Ribosome biogenesis in eukaryotes 2.4 11 2.3e-05
10 04530 Tight junction 4.2 14 6.2e-05
11 04010 MAPK signaling pathway 8.5 21 9e-05
12 04110 Cell cycle 3.9 13 0.00011
13 04510 Focal adhesion 6.4 17 0.00016
14 05222 Small cell lung cancer 2.7 10 0.00028
15 04012 ErbB signaling pathway 2.8 10 0.00034
16 04666 Fc gamma R-mediated phagocytosis 2.9 10 0.00052
17 05160 Hepatitis C 4.2 12 0.00079
18 03015 mRNA surveillance pathway 2.6 9 0.00098
19 05213 Endometrial cancer 1.7 7 0.001
20 04115 p53 signaling pathway 2.2 8 0.0011
21 00620 Pyruvate metabolism 1.3 6 0.0013
22 05146 Amoebiasis 3.4 10 0.0015
23 00970 Aminoacyl-tRNA biosynthesis 1.3 6 0.0015
24 05221 Acute myeloid leukemia 1.8 7 0.0017
25 03040 Spliceosome 4 11 0.0017
26 04630 Jak-STAT signaling pathway 4.9 12 0.0025
27 04910 Insulin signaling pathway 4.4 11 0.0031
28 05214 Glioma 2.1 7 0.0035
29 04916 Melanogenesis 3.2 9 0.0035
30 00230 Purine metabolism 5.1 12 0.0037
31 04210 Apoptosis 2.8 8 0.0047
32 03430 Mismatch repair 0.7 4 0.0049
33 04612 Antigen processing and presentation 2.2 7 0.0051
34 05211 Renal cell carcinoma 2.2 7 0.0051
35 05212 Pancreatic cancer 2.2 7 0.0051
36 04660 T cell receptor signaling pathway 3.4 9 0.0052
37 05145 Toxoplasmosis 4.1 10 0.0057
38 04144 Endocytosis 6.4 13 0.0072
39 05219 Bladder cancer 1.3 5 0.0083
40 03440 Homologous recombination 0.9 4 0.0096
41 00280 Valine, leucine and isoleucine degradation 1.4 5 0.0099
42 04962 Vasopressin-regulated water reabsorption 1.4 5 0.0099
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Figure 4·4: WGCNA trait correlation heatmaps showing the corre-
lation between each module and (a) time points and (b) cell types.
Modules are those shown in Figure 4·3. Spearman correlation coef-
ficients are indicated, with p-values given in parentheses. Significant
(p<0.01) correlations are marked with an asterisk. Colors reflect degree
and direction of correlation, scale shown at right.
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Figure 4·5: WGCNA multidimensional scaling plot of gene modules.
Intramodular “hub” genes are at the tips of the plot (circles). Hub genes
are the genes correlated with the most other genes in the module.
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(33%)
(58%)
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(1%)
Figure 4·6: Frequency of gene occurrence across all cell types. Indi-
cates the percent of genes that are differentially expressed in response
to estrogen in only one cell type (“unique”), in 2-4 cell types (“shared”),
in 5 or 6 cell types (“common”), or in more than 6 cell types (“top”).
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Figure 4·7: Shared vs. unique gene occurrence by cell type. Indicates
the percent of genes that are differentially expressed in response to
estrogen only in that cell type (light gray) or in that cell type and at
least one other cell type (dark gray).
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Figure 4·8: Overlap of top four gene groups. (a) Venn diagram of
the overlap among the top four lists of genes differentially expressed in
response to estrogen in each cell group. (b) Graph showing the percent
of genes in each group that were common to all four groups (dark gray),
shared with some but not all other groups (medium gray), and unique
to that group (light gray).
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Figure 4·9: Pathways and genes involved in cell proliferation. Green
outlines indicate pathways that drive proliferation, black are pathways
that inhibit proliferation and/or drive apoptosis. Key genes in each
pathway are shown.
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Figure 4·10 (following page): Heatmap of proliferation gene expres-
sion. Each row contains data for one gene. Pathways that genes belong
to are indicated in the right margin. Red indicates up-regulation, blue
indicates down-regulation. In cells that are proliferating, the majority
of these genes should be up-regulated (red). In cells that are in cell
cycle arrest or apoptotic, these genes should be down-regulated (blue).
The expected effects of estrogen for each cell type are shown across
the bottom. Each column contains data for one cell type at one time
points, time points are grouped as follows: A = one half to two hours,
B = three to four hours, C1 = six to eight hours, C2 = ten to twelve
hours, D = twenty-four hours, E = two to six days, and F = one to
twelve weeks. Letters after gene symbols indicate known direct or in-
direct binding of ERα: a = direct target; b = indirect target via Sp1;
c = indirect target via AP-1; d = indirect target via NFκB (Jin et al.,
2005).
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Figure 4·11 (following page): Heatmap of anti-proliferation gene
expression. Each row contains data for one gene. Pathways that
genes belong to are indicated in the right margin. Red indicates up-
regulation, blue indicates down-regulation. In cells that are proliferat-
ing, the majority of these genes should be down-regulated (blue). In
cells that are in cell cycle arrest or apoptotic, these genes should be
up-regulated (red). The expected effects of estrogen for each cell type
are shown across the bottom. Each column contains data for one cell
type at one time point; time points are grouped as follows: A = one
half to two hours, B = three to four hours, C1 = six to eight hours, C2
= ten to twelve hours, D = twenty-four hours, E = two to six days, and
F = one to twelve weeks. Letters after gene symbols indicate known
direct or indirect binding of ERα: a = direct target; b = indirect target
via Sp1; c = indirect target via AP-1; d = indirect target via NFκB
(Jin et al., 2005).
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Chapter 5
Conclusion
5.1 Computational Advances
In undertaking a large-scale meta-analysis of estrogen regulation of gene expression,
it was noted that there were several challenges to overcome. Since most of the data
available was of oligonucleotide (microarray) format, the inherent issues with this type
of technology had to be addressed. First addressed was the issue of redundant probes–
multiple probes that hybridize to the same gene–and the need to deconvolute their
signals when they are not in agreement. At the same time, agreement among such
multiple probes was a benefit that was not being tapped. The SCOREM methodology
was developed to take advantage of concordance, to improve statistical confidence in
the results, and report discordance when it occurs. The benefits of this process
depended, however, on the accuracy of the probe annotations, which were known to
be out of date, at best.
Thus, the GRASPEM pipeline was developed, to align all probes to the most
current versions of the genome. It re-annotates and assigns scores to those probes
based on their locations (relative to gene features), quality (number of mismatches
and/or gaps in the alignments), and uniqueness. The new annotations are used when
applying the SCOREM algorithm. Combination of the probe scores with the fold
changes and p-values produced by SCOREM yields weighted scores that allow for
cross-platform comparisons of differential expression.
GRASPEM can be applied to any platform that has probe sequence data available.
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SCOREM can be applied to any type of data with redundant measures. In light of
the increased availability of RNA-seq data, SCOREM can be adapted to be used
with RNA-seq data that has been annotated with gene feature (exon) information,
providing information on exons that are concordant or discordant.
5.2 Biological Advances
The meta-analysis of estrogen-regulated gene expression included 110 experiments
conducted on nineteen different cell or tissue types and twenty-four different ex-
pression platforms. The GRASPEM pipeline was applied to all platforms for which
sequence data was available, and the SCOREM method utilized to generate weighted
scores for all experiments. Comparison of the genes regulated by estrogen showed
significant overlap across these diverse experiments, as did the functional pathways
enriched in those genes. Most notably, the pathways involved in cell proliferation
were markedly enriched in several of these cell types. In breast cancer cells positive
for estrogen receptors, as well as uterine tissue, genes that promote cell proliferation
were up-regulated, and genes that inhibit proliferation were notably down regulated.
In breast cancer cells negative for estrogen receptors, no such regulation was seen. In
vascular smooth muscle cells, neither set of genes showed much change. This shows
that estrogenic control of cell proliferation depends upon the presence of estrogen
receptors and likely involves different mechanisms in cells in which estrogen drives
proliferation vs. those in which estrogen inhibits proliferation.
5.3 Future Directions
Further computational work is planned to expand the annotation base to additional
and different types of sources, i.e., including Ensembl annotated transcripts as well
as RefSeq ones. A web interface can be developed to allow the user to perform the
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analysis at any desktop computer, from selection of data in GEO to visualization of
discords and differentially regulated genes in pathways. Extension of the SCOREM
algorithm to application to RNA-seq data is planned, as more of this type of data is
expected to be available in the future.
Further biological work would expand the data set of the meta-analysis to in-
clude other tissues (bone, brain) as well as other data formats (RNA-seq). It would
also incorporate DNA binding data (ChIP-chip or ChIP-seq) to elucidate which tran-
scriptional regulatory targets of estrogen are direct targets (having estrogen receptor
binding elements in their promoters) or indirect targets. Finally, the prediction that
control of proliferation in vascular smooth muscle cells does not involve control of cell
cycle genes may be experimentally validated, for instance by RT-PCR of some key
genes.
103
Appendix
Table A.1: All experiments included in the meta-analysis. Time
points were grouped as follows: A = one half to two hours, B
= three to four hours, C1 = six to eight hours, C2 = ten to
twelve hours, D = twenty-four hours, E = two to six days, and
F = one to twelve weeks. Treatments were either E2vPL (estrogen
vs. placebo) or FvO (female vs. ovarioectomized female).
Experiment ID Species Cell Type Time Treatments Platform
ASMC Schnoes et al. (2008) Mm ASMC A E2vPL mouse4302
ASMC Schnoes et al. (2008) Mm ASMC B E2vPL mouse4302
ASMC Schnoes et al. (2008) Mm ASMC C1 E2vPL mouse4302
GSE9371 Mm ASMC F E2vPL mouse4302
GSE3834 Hs BT474 A E2vPL hgu133plus2
GSE3834 Hs BT474 B E2vPL hgu133plus2
GSE3834 Hs BT474 C1 E2vPL hgu133plus2
GSE3834 Hs BT474 C2 E2vPL hgu133plus2
GSE3529 Hs BT474 D E2vPL hgu133a
GSE3834 Hs BT474 D E2vPL hgu133plus2
GSE9098 Mm cd44-stromal F E2vPL mouse4302
GSE9098 Mm ckit-stem F E2vPL mouse4302
GSE22600 Hs EOC F E2vPL hgu133plus2
GSE22600 Hs EOC F E2vPL hgu133plus2
GonFat Grove et al. (2010) Mm GonFat F FvO mouse4302
GSE22941 Hs HeLa B E2vPL GPL6947
IngFat Grove et al. (2010) Mm IngFat F FvO mouse4302
GSE3762.GPL2914 Hs Ishikawa D E2vPL GPL2914
GSE3762.GPL3218 Hs Ishikawa D E2vPL GPL3218
GSE3762.GPL2914 Hs Ishikawa E E2vPL GPL2914
GSE3762.GPL3218 Hs Ishikawa E E2vPL GPL3218
GSE4782 Rn MASMC E E2vPL GPL2890
GSE23037 Rn MASMC F E2vPL GPL2896
GSE22012 Hs MCF7 A E2vPL GPL6480
GSE3834 Hs MCF7 A E2vPL hgu133plus2
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GSE11467 Hs MCF7 A E2vPL hgu133a
GSE3834 Hs MCF7 A E2vPL hgu133plus2
GSE11324 Hs MCF7 B E2vPL hgu133plus2
GSE11506 Hs MCF7 B E2vPL hgu133plus2
GSE26834 Hs MCF7 B E2vPL hgu133a2
GSE9253 Hs MCF7 B E2vPL hgu133plus2
GSE10618 Hs MCF7 B E2vPL GPL990
GSE15717 Hs MCF7 B E2vPL hgu133a
GSE24592 Hs MCF7 B E2vPL hgu133a2
GSE3834 Hs MCF7 B E2vPL hgu133plus2
GSE5840 Hs MCF7 B E2vPL hgu133plus2
GSE11324 Hs MCF7 C1 E2vPL hgu133plus2
GSE11506 Hs MCF7 C1 E2vPL hgu133plus2
GSE11791 Hs MCF7 C1 E2vPL hgu133plus2
GSE25314 Hs MCF7 C1 E2vPL GPL6947
GSE3834 Hs MCF7 C1 E2vPL hgu133plus2
GSE848 Hs MCF7 C1 E2vPL hgu95a
GSE24065 Hs MCF7 C2 E2vPL GPL6480
GSE10618 Hs MCF7 C2 E2vPL GPL990
GSE11324 Hs MCF7 C2 E2vPL hgu133plus2
GSE11352 Hs MCF7 C2 E2vPL hgu133plus2
GSE22213 Hs MCF7 C2 E2vPL GPL6947
GSE26740 Hs MCF7 C2 E2vPL GPL6883
GSE3834 Hs MCF7 C2 E2vPL hgu133plus2
GSE11352 Hs MCF7 D E2vPL hgu133plus2
GSE24592 Hs MCF7 D E2vPL hgu133a2
GSE26834 Hs MCF7 D E2vPL hgu133a2
GSE27375 Hs MCF7 D E2vPL GPL6947
GSE3529 Hs MCF7 D E2vPL hgu133a
GSE3834 Hs MCF7 D E2vPL hgu133plus2
GSE4006 Hs MCF7 D E2vPL hgu133a
GSE4025 Hs MCF7 D E2vPL hgu133a
GSE6800 Hs MCF7 D E2vPL hgu133plus2
GSE8597 Hs MCF7 D E2vPL hgu133plus2
GSE11352 Hs MCF7 E E2vPL hgu133plus2
GSE4668 Hs MCF7 E E2vPL hgu133a
GSE4668 Hs MCF7 E E2vPL hgu133a
GSE4668 Hs MCF7 E E2vPL hgu133a
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GSE4668 Hs MCF7 E E2vPL hgu133a
GSE5200 Hs MCF7 E E2vPL hgu133a
GSE848 Hs MCF7 E E2vPL hgu95a
GSE15249 Hs MCF7 E E2vPL GPL8307
GSE1045 Hs MDAMB231 A E2vPL hgu133a
GSE1045 Hs MDAMB231 A E2vPL hgu133a
GSE22593 Hs MDAMB231 D E2vPL hgu133a
GSE9117 Rn myometrium C1 E2vPL rgu34a
GSE9117 Rn myometrium D E2vPL rgu34a
GSE11567 Hs SKBR3 A E2vPL GPL6102
GSE3834 Hs T47D A E2vPL hgu133plus2
GSE3834 Hs T47D A E2vPL hgu133plus2
GSE3834 Hs T47D B E2vPL hgu133plus2
GSE3834 Hs T47D C1 E2vPL hgu133plus2
GSE3834 Hs T47D C2 E2vPL hgu133plus2
GSE3529 Hs T47D D E2vPL hgu133a
GSE3834 Hs T47D D E2vPL hgu133plus2
GSE13265 Mm whole.liver F FvO GPL2510
GSE13265 Mm whole.liver F E2vPL GPL2510
GSE13265 Mm whole.liver F E2vPL GPL2510
GSE13265 Mm whole.liver F E2vPL GPL2510
GSE13265 Mm whole.liver F E2vPL GPL2510
GSE5483.GPL81 Mm whole.mamm E E2vPL mgu74av2
GSE5483.GPL82 Mm whole.mamm E E2vPL mgu74bv2
GSE5483.GPL83 Mm whole.mamm E E2vPL mgu74cv2
GSE2889 Mm whole.thymus E E2vPL moe430a
GSE2889 Mm whole.thymus E E2vPL moe430a
GSE2889 Mm whole.thymus E E2vPL moe430a
GSE4664 Mm whole.uterus A E2vPL GPL891
GSE2195 Mm whole.uterus A E2vPL mgu74av2
GSE18168 Mm whole.uterus A E2vPL GPL4134
GSE2195 Mm whole.uterus A E2vPL mgu74av2
GSE4615 Mm whole.uterus A E2vPL GPL891
GSE4664 Mm whole.uterus A E2vPL GPL891
GSE2195 Mm whole.uterus B E2vPL mgu74av2
GSE4664 Mm whole.uterus C1 E2vPL GPL891
GSE2195 Mm whole.uterus C1 E2vPL mgu74av2
GSE4664 Mm whole.uterus C2 E2vPL GPL891
GSE18168 Mm whole.uterus D E2vPL GPL4134
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GSE2195 Mm whole.uterus D E2vPL mgu74av2
GSE23072 Mm whole.uterus D E2vPL GPL4134
GSE23241 Mm whole.uterus D E2vPL GPL4134
GSE4615 Mm whole.uterus D E2vPL GPL891
GSE4664 Mm whole.uterus D E2vPL GPL891
GSE2195 Mm whole.uterus E E2vPL mgu74av2
GSE1839 Mm whole.uterus E E2vPL mgu74av2
GSE2195 Mm whole.uterus E E2vPL mgu74av2
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Table A.2: Statistical significance of gene list overlap between all
pairs of cell types. |A| and |B| indicate the size of the two lists.
|A∩B|obs is the observed size of the intersection. |A∩B|exp is the
expected size of the intersection (Equation 4.3). J is the Jaccard
index (Equation 4.2) and p(χ2) is the p-value for the χ2 test on
the observed and expected values.
Cell Types |A| |B| |A ∩B|obs |A ∩B|exp J p(χ2)
cd44-ckit 119 70 53 0 0.39 < 10−300
MCF7-T47D 4323 2786 1210 486 0.21 < 10−300
whole.uterus-MCF7 4920 4323 1726 858 0.23 2× 10−290
MCF7-EOC 4323 2349 939 410 0.16 2× 10−199
whole.uterus-T47D 4920 2786 1086 553 0.16 6× 10−154
whole.uterus-EOC 4920 2349 841 466 0.13 5× 10−87
T47D-EOC 2786 2349 501 264 0.11 4× 10−59
T47D-BT474 2786 189 101 21 0.04 2× 10−70
MCF7-BT474 4323 189 119 33 0.03 7× 10−53
MCF7-MCF10F 4323 367 177 64 0.04 2× 10−48
GonFat-IngFat 262 126 17 1 0.05 3× 10−44
SKBR3-whole.liver 40 173 6 0 0.03 3× 10−28
ASMC-MASMC 179 71 8 1 0.03 1× 10−26
whole.uterus-GonFat 4920 262 121 52 0.02 1× 10−22
whole.uterus-ASMC 4920 179 90 36 0.02 1× 10−20
SKBR3-cd44 40 119 4 0 0.03 1× 10−18
T47D-Ishikawa 2786 135 49 15 0.02 1× 10−18
SKBR3-MASMC 40 71 3 0 0.03 5× 10−18
whole.uterus-BT474 4920 189 89 38 0.02 1× 10−17
MDAMB231-SKBR3 34 40 2 0 0.03 3× 10−17
MASMC-whole.liver 71 173 6 0 0.03 2× 10−15
cd44-GonFat 119 262 10 1 0.03 2× 10−15
whole.uterus-IngFat 4920 126 64 25 0.01 3× 10−15
ASMC-GonFat 179 262 12 2 0.03 7× 10−14
SKBR3-MCF7 40 4323 26 7 0.01 4× 10−13
whole.uterus-SKBR3 4920 40 28 8 0.01 8× 10−13
ASMC-whole.liver 179 173 9 1 0.03 1× 10−12
MDAMB231-MCF7 34 4323 23 6 0.01 1× 10−12
MDAMB231-HeLa 34 15 1 0 0.02 5× 10−12
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SKBR3-BT474 40 189 4 0 0.02 1× 10−11
whole.mamm-whole.liver 26 173 3 0 0.02 2× 10−11
HeLa-myometrium 15 37 1 0 0.02 4× 10−11
whole.uterus-whole.liver 4920 173 72 34 0.01 7× 10−11
MCF7-cd44 4323 119 50 21 0.01 8× 10−11
SKBR3-HeLa 40 15 1 0 0.02 2× 10−10
MCF7-ASMC 4323 179 66 31 0.01 2× 10−10
HeLa-whole.liver 15 173 2 0 0.01 3× 10−09
whole.uterus-MASMC 4920 71 36 14 0.01 4× 10−09
MDAMB231-T47D 34 2786 15 4 0.01 9× 10−09
SKBR3-ckit 40 70 2 0 0.02 1× 10−08
BT474-EOC 189 2349 41 18 0.02 3× 10−08
whole.mamm-whole.thymus 26 114 2 0 0.01 4× 10−08
SKBR3-T47D 40 2786 16 4 0.01 5× 10−08
MCF7-IngFat 4323 126 47 22 0.01 6× 10−08
whole.uterus-cd44 4920 119 49 24 0.01 1× 10−07
T47D-ASMC 2786 179 43 20 0.01 2× 10−07
whole.uterus-whole.mamm 4920 26 16 5 0.00 1× 10−06
T47D-whole.mamm 2786 26 11 3 0.00 2× 10−06
whole.thymus-cd44 114 119 4 1 0.02 2× 10−06
EOC-IngFat 2349 126 28 12 0.01 2× 10−06
T47D-GonFat 2786 262 54 29 0.02 4× 10−06
MCF7-ckit 4323 70 28 12 0.01 5× 10−06
whole.uterus-Ishikawa 4920 135 50 27 0.01 5× 10−06
ckit-IngFat 70 126 3 0 0.02 7× 10−06
whole.liver-IngFat 173 126 5 1 0.02 8× 10−06
cd44-IngFat 119 126 4 1 0.02 1× 10−05
ASMC-IngFat 179 126 5 1 0.02 1× 10−05
whole.uterus-whole.thymus 4920 114 43 23 0.01 1× 10−05
whole.uterus-myometrium 4920 37 19 7 0.00 1× 10−05
MCF7-whole.liver 4323 173 53 30 0.01 2× 10−05
MCF7-MASMC 4323 71 27 12 0.01 2× 10−05
MCF7-GonFat 4323 262 73 46 0.02 3× 10−05
MCF7-whole.mamm 4323 26 13 5 0.00 6× 10−05
whole.uterus-MDAMB231 4920 34 17 7 0.00 7× 10−05
ckit-GonFat 70 262 4 1 0.01 1× 10−04
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Ishikawa-EOC 135 2349 26 13 0.01 1× 10−04
whole.thymus-whole.liver 114 173 4 1 0.01 2× 10−04
whole.liver-cd44 173 119 4 1 0.01 4× 10−04
myometrium-whole.liver 37 173 2 0 0.01 5× 10−04
whole.mamm-ckit 26 70 1 0 0.01 5× 10−04
MDAMB231-BT474 34 189 2 0 0.01 5× 10−04
ASMC-cd44 179 119 4 1 0.01 6× 10−04
whole.mamm-MASMC 26 71 1 0 0.01 6× 10−04
BT474-whole.thymus 189 114 4 1 0.01 6× 10−04
BT474-MASMC 189 71 3 1 0.01 7× 10−04
whole.mamm-GonFat 26 262 2 0 0.01 9× 10−04
EOC-GonFat 2349 262 41 25 0.02 9× 10−04
MDAMB231-EOC 34 2349 9 3 0.00 1× 10−03
HeLa-Ishikawa 15 135 1 0 0.01 1× 10−03
MCF7-Ishikawa 4323 135 39 24 0.01 1× 10−03
T47D-MASMC 2786 71 17 8 0.01 1× 10−03
whole.uterus-ckit 4920 70 25 14 0.01 2× 10−03
whole.thymus-ckit 114 70 2 0 0.01 2× 10−03
MDAMB231-ckit 34 70 1 0 0.01 3× 10−03
EOC-whole.liver 2349 173 28 16 0.01 3× 10−03
myometrium-ckit 37 70 1 0 0.01 5× 10−03
myometrium-MASMC 37 71 1 0 0.01 5× 10−03
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Table A.3: Number of experiments and genes included in each gene
signature, for each cell type and time. Time points were grouped as
follows: A = one half to two hours, B = three to four hours, C1 = six
to eight hours, C2 = ten to twelve hours, D = twenty-four hours, E =
two to six days, and F = one to twelve weeks.
Cell Time Experiments Genes
MCF7 A 4 83
B 13 1343
C1 6 807
C2 7 1719
D 22 1885
E 11 2004
T47D A 5 1360
B 2 1536
C1 4 1981
C2 4 1811
D 2 1901
BT474 A 1 96
B 1 50
C1 1 55
C2 1 40
D 2 84
wh.mamm E 3 26
wh.uterus A 10 446
B 1 1250
C1 2 391
C2 1 44
D 11 3461
E 3 1352
myometrium C1 1 15
D 1 25
HeLa B 1 15
Ishikawa D 2 121
E 2 32
EOC F 3 2357
MDAMB231 A 8 4
D 3 30
SKBR3 A 1 40
ASMC A 1 13
B 1 18
C1 1 63
F 9 101
MASMC E 1 67
F 1 4
wh.thymus E 3 15
cd44 F 1 119
ckit F 1 70
GonFat F 3 262
IngFat F 3 126
wh.liver F 12 173
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Table A.4: Top KEGG pathways enriched in five WGCNA modules.
Rank KEGG Pathway Exp # Obs # P-value
Black
1 03030 DNA replication 1.2 17 3.1e-16
2 04110 Cell cycle 4.1 24 2.1e-12
3 03430 Mismatch repair 0.8 9 2.5e-08
4 01100 Metabolic pathways 37.5 69 4.2e-07
5 00230 Purine metabolism 5.4 18 6.3e-06
6 03410 Base excision repair 1.1 8 8.9e-06
7 00970 Aminoacyl-tRNA biosynthesis 1.4 8 4.7e-05
8 00240 Pyrimidine metabolism 3.3 12 8.8e-05
9 03013 RNA transport 5 14 0.00038
10 03420 Nucleotide excision repair 1.5 7 0.00049
Blue
1 04141 Protein processing in endoplasmic reticulum 4.3 14 8.9e-05
2 04810 Regulation of actin cytoskeleton 5.6 14 0.00099
3 00100 Steroid biosynthesis 0.5 4 0.0012
4 01100 Metabolic pathways 29.4 45 0.0013
5 04010 MAPK signaling pathway 7 14 0.0064
6 00020 Citrate cycle (TCA cycle) 0.8 4 0.0065
7 00480 Glutathione metabolism 1.3 5 0.0079
Green
1 04110 Cell cycle 1.2 13 2.7e-10
2 03440 Homologous recombination 0.3 7 8.2e-09
3 04114 Oocyte meiosis 1.1 9 1.6e-06
4 00240 Pyrimidine metabolism 1 8 5.8e-06
5 04914 Progesterone-mediated oocyte maturation 0.8 7 2.1e-05
6 01100 Metabolic pathways 11.1 24 2e-04
7 03410 Base excision repair 0.3 4 0.00029
8 00900 Terpenoid backbone biosynthesis 0.1 3 0.00039
9 03030 DNA replication 0.4 4 4e-04
10 05215 Prostate cancer 0.9 5 0.0017
Purple
1 05145 Toxoplasmosis 0.8 6 0.00018
2 05200 Pathways in cancer 2.1 9 0.00023
3 05014 Amyotrophic lateral sclerosis (ALS) 0.3 4 0.00036
4 05217 Basal cell carcinoma 0.4 4 0.00041
5 04115 p53 signaling pathway 0.4 4 0.00091
6 04976 Bile secretion 0.5 4 0.0011
7 00790 Folate biosynthesis 0.1 2 0.0021
8 04972 Pancreatic secretion 0.6 4 0.0036
9 00480 Glutathione metabolism 0.3 3 0.0038
10 00511 Other glycan degradation 0.1 2 0.0051
Turquoise
1 01100 Metabolic pathways 75.4 143 3.5e-14
2 05215 Prostate cancer 6 30 4e-14
3 03040 Spliceosome 8.5 34 1.5e-12
4 05220 Chronic myeloid leukemia 4.9 25 3.5e-12
5 04910 Insulin signaling pathway 9.3 35 3.8e-12
6 04141 Protein processing in endoplasmic reticulum 11.1 38 1.1e-11
7 03013 RNA transport 10.1 35 5.7e-11
8 05200 Pathways in cancer 21.9 55 1.5e-10
9 05213 Endometrial cancer 3.5 19 3.7e-10
10 05221 Acute myeloid leukemia 3.8 19 2.2e-09
Exp # = number of genes from this pathway expected to be a module of this size. Obs # = number
of genes from this pathway observed in this module. Purple and green modules contain genes whose
behavior is highly correlated with cell type (Figure 4·4). Blue, black, and turquoise modules showed
strong intra-modular similarity (Figure 4·5). The top pathways from Table 4.5 are shown in italics.
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